

**SWOG
PUBLICATIONS LIST
BREAST COMMITTEE
2017**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
Breast Manuscripts Published/Accepted (2017)			
S0221	Supplement use and chemotherapy-induced peripheral neuropathy in patients treated in a SWOG cooperative group trial (S0221): the DELCaP Study. G Zirpoli, S McCann, L Sucheston-Campbell, D Hershman, G Ciupak, W Davis, J Unger, H Moore, JA Stewart, C Isaacs, T Hobday, M Salim, R Livingston, G Hortobagyi, J Gralow, D Hayes, G Budd, K Albain, C Ambrosone. <u>Journal of the National Cancer Institute</u> , accepted. [see also SXCQOL Cmte]	11/01/03	1/15/12
S9630/Multiple	How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? KD Crew, KS Albain, DL Hershman, JM Unger, SS Lo. <u>NPJ Breast Cancer</u> , May 19;3:20, 2017. [commentary]. doi: 10.1038/s41523-017-0021-y. eCollection 2017. PMID28649660; PMC5460136 https://www.ncbi.nlm.nih.gov/pubmed/28649660 [see also Prevention Committee]	3/15/97	12/15/04
CCTG/MA.27	Osteoporosis therapy prolongs event-free survival in post-menopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27. A Lipton, JW Chapman, K Leitzel, A Garg, KI Pritchard, J Ingle, GT Budd, M Ellis, G Sledge, M Rabaglio, L Han, C Elliott, LE Shepherd, PE Goss, SM Ali. Pending revision and submission <u>Cancer</u> Jul 1;123(13):2444-2451. Epub 2017 May 2. PMID28464211 https://www.ncbi.nlm.nih.gov/pubmed/28464211	11/15/98	8/31/02
CCTG MA.32	Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. AE Lohmann, MF Liebman, W Brien, WR Parulekar, KA Gelmon, LE Shepherd, JA Ligibel, DL Hershman, P Rastogi, IA Mayer, TJ Hobday, J Lemieux, AM Thompson, KI Pritchard, TJ Whelan, SD Mukherjee, HI Chalchal, V Bernstein, V Stambolic, BE Chen, PJ Goodwin. From the CCTG, Alliance, SWOG, ECOG, NSABP Cooperative Groups. <u>Breast Cancer Research and Treatment</u> Jul;164(2):371-378, 2017. Epub 2017 Apr 26. PMID28447237 https://www.ncbi.nlm.nih.gov/pubmed/28447237	9/15/10	1/22/13
Z1071	Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from ACOSOG Z1071 (Alliance). JC Boughey, KV Ballman, LM McCall, EA Mittendorf, WF Symmans, TB Julian, D Byrd, KK Hunt. <u>Annals of Surgery</u> Jun 27 [Epub ahead of print], 2017. PMID28657941 https://www.ncbi.nlm.nih.gov/pubmed/28657941		

Breast Manuscripts Submitted (2017)

- S9313 Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313). P Sharma, WE Barlow, AK Godwin, H Pathak, K Isakova, KM Timms, AR Hartman, RJ Wenstrup, HM Linden, D Tripathy, GN Hortobagyi, DF Hayes. Journal of Clinical Oncology, under review.
- S0800 Effects of neoadjuvant chemotherapy on tumor infiltrating lymphocytes and PD-L1 expression in the SWOG S0800 clinical trial. V Pelekanou, WE Barlow, ZA Nahleh, B Wasserman, Y-C Lo, M-K von Wahlde, D Hayes, GN Hortobagyi, J Gralow, D Tripathy, P Porter, RB Livingston, B Szekely, C Hatzis, DL Rimm, L Pusztai. JAMA Oncology, under review.

Breast Abstracts Present/Published/Accepted (2017)

- | | | | |
|-------|--|----------|---------|
| S0221 | SWOG S0221 Updated: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. GT Budd, WE Barlow, HCF Moore, TJ Hobday, JA Stewart, C Isaacs, M Salim, JK Cho, K Rinn, KS Albain, HK Chew, G Von Burton, TD Moore, G Srkalovic, B McGregor, LE Flaherty, RB Livingston, D Lew, J Gralow, GN Hortobagyi. American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster session; J Clin Oncol 35, 2017 (suppl; abstr 521).
http://abstracts.asco.org/199/AbstView_199_184069.html | 11/01/03 | 1/15/12 |
| S0800 | Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial. V Pelekanou, WE Barlow, M-C von Wahlde, B Wasserman, Y-C Lo, D Hayes, GN Hortobagyi, J Gralow, D Tripathy, R Livingston, ZA Nahleh, DL Rimm, L Pusztai. American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion; J Clin Oncol 35, 2017 (suppl; abstr 519).
http://abstracts.asco.org/199/AbstView_199_189568.html | 4/1/10 | 10/1/12 |
| S9313 | Impact of homologous recombination deficiency (HRD) biomarkers on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313). P Sharma, W Barlow, AK Godwin, H Pathak, K Isakova, AR Hartman, RJ Wenstrup, HM Linden, D Tripathy, GN Hortobagyi, DF Hayes. AACR Annual Meeting (April 1-5, 2017, Washington, DC), poster. Proceedings of the American Association for Cancer Research April 2017 Vol 58, abstr. 1776 p. 456.
http://www.aacr.org/Documents/AACR2017_Proceedings.pdf | 3/15/94 | 5/1/97 |
| S9313 | Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313). P Sharma, W Barlow, AK Godwin, L Knight, SM Walker, RD Kennedy, S Badve, Y Gökmen-Polar, H Pathak, K Isakova, H Linden, D Tripathy, G Hortobagyi, D Hayes. American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster session; J Clin Oncol 35, 2017 (suppl; abstr 529).
http://abstracts.asco.org/199/AbstView_199_193082.html | 3/15/94 | 5/1/97 |

**SWOG
PUBLICATIONS LIST
BREAST COMMITTEE
2016**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
Breast Manuscripts Published (2016)			
S0226	Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. D Hertz, W Barlow, K Kidwell, K Albain, T Vandenberg, S Dakhil, N Tirumali, R Livingston, J Gralow, D Hayes, G Hortobagyi, R Mehta, J Rae. <i>British Journal of Clinical Pharmacology</i> , Jun;81(6):1134-1141, 2016; 2016 Feb 9 [Epub ahead of print]. PMID26859101 http://www.ncbi.nlm.nih.gov/pubmed/26859101	4/1/04	7/1/09
S0622	Phase II studies of two different schedules of dasatinib in bone-metastasis predominant metastatic breast cancer: SWOG S0622. AF Schott, WE Barlow, CH Van Poznak, DF Hayes, CM Moinpour, DL Lew, CM Reynolds; PA Dy, E Keller, J Keller, GN Hortobagyi. <i>Breast Cancer Research and Treatment</i> , Aug;159(1):87-95, 2016; 2016 Jul 30 [Epub ahead of print]. PMID27475087; PMC5021222 http://www.ncbi.nlm.nih.gov/pubmed/27475087	3/15/07	12/15/10
S0800	SWOG S0800 (NCI CDR0000636131): Addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer: Z Nahleh, W Barlow, D Hayes, A Schott, J Gralow, E Perez, W Sikov, S Chennuru, H Mirshahidi, S Corso, D Lew, L Pusztai, R Livingston, G Hortobagyi. <i>Breast Cancer Research and Treatment</i> , Aug;158(3):485-495, 2016; 2016 Jul 8 [Epub ahead of print]. PMID27393622; PMC4963434 http://www.ncbi.nlm.nih.gov/pubmed/27393622	4/1/10	10/1/12
S1416	Breast cancer outlook for 2017: keeping the accelerator to the floor. VK Gadi, JR Gralow. <i>Oncology (Williston Park)</i> , 30(12 suppl 2):1-2, 2016. [review] PMID27933601. https://www.ncbi.nlm.nih.gov/pubmed/27933601		
S9630	A phase III randomized comparison of medroxy-progesterone acetate versus observation for the prevention of endometrial pathology in postmenopausal patients with breast cancer treated with adjuvant tamoxifen: SWOG S9630. RK Potkul, JM Unger, RB Livingston, S Wilczynski, C Salomon, B Smith, L Wong, DL Campbell, SJ Vogel, GL Anderson, GE Goodman, PH Brown, FL Meyskens, KS Albain. <i>NPJ Breast Cancer</i> , Aug 10;2:16024, 2016. PMID28721383; PMC5515330 https://www.ncbi.nlm.nih.gov/pubmed/28721383	3/15/97	12/15/04

C9741	PAM50 gene signatures are prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy in C9741 (Alliance). MC Liu, BN Pitcher, ER Mardis, SR Davies, JE Snider, TL Vickery, JP Reed, K DeSchryver, B Singh, PN Friedman, WJ Gradishar, EA Perez, S Martino, ML Citron, L Norton, EP Winer, CA Hudis, LA Carey, TO Nielsen, CM Perou, MJ Ellis, WT Barry. <u>NPJ Breast Cancer</u>. 2016;2. pii: 15023. doi: 10.1038/npjbcancer.2015.23. Epub 2016 Jan 6. PMID28691057; PMC5501351 https://www.ncbi.nlm.nih.gov/pubmed/?term=Liu+MC+c9741	7/1/198	3/31/99
C40503	Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance). MN Dickler, WT Barry, CT Cirrincione, MJ Ellis, ME Moynahan, F Innocenti, A Hurria, HS Rugo, DE Lake, O Hahn, BP Schneider, D Tripathy, LA Carey, EP Winer, CA Hudis. <u>Journal of Clinical Oncology</u> Aug 1;34(22):2602-2609, 2016. PMID27138575; PMC5012690 http://www.ncbi.nlm.nih.gov/pubmed/27138575	5/15/10	11/15/11
C40601	Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. LA Carey, DA Berry, CT Cirrincione, WT Barry, BN Pitcher, LN Harris, DW Ollila, IE Krop, NL Henry, DJ Weckstein, CK Anders, B Singh, KA Hoadley, M Iglesia, MCU Cheang, CM Perou, EP Winer, CA Hudis. <u>Journal of Clinical Oncology</u>, Feb 20;34(6):542-549, 2016. PMID26527775; PMC4980567 http://www.ncbi.nlm.nih.gov/pubmed/?term=carey+la+40601	12/15/08	2/29/12
C40601	Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). M Golshan, CT Cirrincione, WM Sikov, LA Carey, DA Berry, B Overmoyer, NL Henry, G Somlo, E Port, HJ Burstein, C Hudis, E Winer, DW Ollila. <u>Breast Cancer Research and Treatment</u> Nov 2016, 160 (2):297–304. PMID27704226; PMC5189982. https://www.ncbi.nlm.nih.gov/pubmed/27704226	12/15/08	2/29/12
C49907	Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer. Alliance A171201, an ancillary study of CALGB/CTSUS 49907. SM Lichtman, CT Cirrincione, A Hurria, A Jatoi, M Theodoulou, AC Wolff, J Gralow, D Morganstern, G Magrinat, HJ Cohen, H Muss for the Alliance for Clinical Trials in Oncology. <u>Journal of Clinical Oncology</u>, 2016 Mar 1;34(7):699-705, 2016; 2016 Jan 11 [Epub ahead of print]. PMID26755510; PMC4872024 http://www.ncbi.nlm.nih.gov/pubmed/26755510	7/15/02	12/29/06

MA.17 & 17R	Extending aromatase-inhibitor adjuvant therapy to 10 years. PE Goss, JN Ingle, KI Pritchard, NJ Robert, H Muss, J Gralow, K Gelmon, T Whelan, K Strasser-Weippl, S Rubin, K Sturtz, AC Wolff, E Winer, C Hudis, A Stopeck, JT Beck, JS Kaur, K Whelan, D Tu, WR Parulekar. <i>New England Journal of Medicine</i> Jul 21;375(3):209-219, 2016. PMID27264120; PMC5024713 http://www.ncbi.nlm.nih.gov/pubmed/27264120		
NRG B-35	Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. P Ganz, R Cecchini, T Julian, R Margolese, J Costantino, L Vallow, K Albain, P Whitworth, M Cianfrocca, A Brufsky, H Gross, G Soori, J Hopkins, L Fehrenbacher, K Sturtz, T Wozniak, T Seay, E Mamounas, N Wolmark. <i>Lancet</i> Feb 27;387(10021):857-65, 2016. 2015 Dec 10 [Epub ahead of print]. PMID26686960 PMC4792658 http://www.ncbi.nlm.nih.gov/pubmed/26686960 [see also SXCQOL Committee]	7/1/03	6/15/06
NRG B-35	Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. R Margolese, R Cecchini, T Julian, P Ganz, J Costantino, L Vallow, K Albain, P Whitworth, M Cianfrocca, A Brufsky, H Gross, G Soori, J Hopkins, L Fehrenbacher, K Sturtz, T Wozniak, T Seay, E Mamounas, N Wolmark. <i>Lancet</i> , Feb 27;387(10021):849-856, 2016 PMID26686957; PMC4792688 http://www.ncbi.nlm.nih.gov/pubmed/26686957	7/1/03	6/15/06
Z1071	Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: results from ACOSOG Z1071 (Alliance). BG Haffty, LM McCall, KV Ballman, S McLaughlin, R Jagsi, DW Ollila, KK Hunt, TA Buchholz, JC Boughey. <i>Int J Radiation Oncol Biol Phys</i> , 94(3):493-502, 2016. PMID26867878; PMC4752720 http://www.ncbi.nlm.nih.gov/pubmed/26867878	12/1/09	5/29/12

Breast Abstracts Published/Presented (2016)

S0221	Supplement use and chemotherapy-induced peripheral neuropathy in breast cancer patients treated on SWOG study S0221. G Zirpoli, S McCann, L Sucheston-Campbell, D Hershman, G Ciupak, W Davis, J Unger, H Moore, JA Stewart, C Isaacs, T Hobday, M Salim, R Livingston, G Hortobagyi, J Gralow, D Hayes, G Budd, K Albain, C Ambrosone. American Association for Cancer Research Annual Meeting (April 16 - 20, 2016, New Orleans, LA), #3413, poster presentation. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=cb63b42a-9a19-44c8-a0bf-1e906d50a77f&cKey=512f1e18-ff52-4b7e-9269-35748cfd1c3&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267 [report only with SCQOL Committee]	11/01/03	1/15/12
-------	--	----------	---------

S8814	Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814. KS Albain, MR Crager, WE Barlow, FL Baehner, A Bergamaschi, JM Rae, PM Ravdin, D Tripathy, JR Gralow, RB Livingston, CK Osborne, JN Ingle, KI Pritchard, NE Davidson, LA Carey, DB Cherbavaz, AP Sing, S Shak, GN Hortobagyi, DF Hayes. San Antonio Breast Cancer Symposium (Dec 6-10, 2016, San Antonio, TX), poster discussion, #PD7-07. http://www.abstracts2view.com/sabcs/view.php?nu=SABCS16L_1031	5/15/89	8/1/95
S8814	The 21-gene recurrence score and locoregional recurrence rates in patients with node-positive breast cancer treated on SWOG S8814. W Woodward, W Barlow, R Jagsi, T Buchholz, S Shak, F Baehner, C Yoshizawa, T Whelan, N Davidson, J Ingle, T King, P Ravdin, C Osborne, D Tripathy, R Livingston, J Gralow, G Hortobagyi, D Hayes, K Albain. ASTRO Annual Meeting (September 25 - 28, 2016, Boston, MA), oral presentation. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):S146. http://ac.els-cdn.com/S0360301616306800/1-s2.0-S0360301616306800-main.pdf?_tid=203f4038-94ab-11e6-a2a3-00000aab0f6c&acdnat=1476737518_44f287055157c03aaf1cdefb21a564e5	5/15/89	8/1/95
S8897	Germline genetic variants in GATA3 and breast cancer treatment outcomes in SWOG S8897 trial. V Larsen, WE Barlow, JJ Yang, Q Zhu, S Liu, LF Hutchins, SA Kadlubar, KS Albain, RB Livingston, JM Rae, I-T Yeh, PM Ravdin, S Martino, AP Lyss, CK Osborne, GN Hortobagyi, DF Hayes, CB Ambrosone, S Yao. American Association for Cancer Research Annual Meeting (April 16 - 20, 2016, New Orleans, LA), poster presentation, abstr #2032. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=e8ca45c3-6dd4-42b8-aa09-81f7aa1bb129&cKey=38404e36-a616-4c25-8b67-4e93c5835772&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267	7/15/89	2/1/93
S9630	Randomized trial of medroxyprogesterone acetate for prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630 (ClinicalTrials.gov NCT00002920). KS Albain, JM Unger, RB Livingston, KD Crew, SP Wilczynski, CG Salomon, BL Smith, L Wong, D Campbell, DE Einspahr, GL Anderson, DL Hershman, GE Goodman, P Brown, FL Meyskens, R Potkul. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session; J Clin Oncol 34, 2016 (suppl; abstr 547). http://abstract.asco.org/176/AbstView_176_167358.html [see also Prevention Committee]	3/15/97	12/15/04
C40503	Identifying risk factors for toxicity in patients with hormone-receptor positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (Alliance) correlative study. D Li, MN Dickler, LM McCall, OM Hahn, CA Hudis, HJ Cohen, HB Muss, KV Ballma, EP Winer, D Tripathy, B Schneider, CT Cirincione, W Barry, A Hurria. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session. J Clin Oncol 34, 2016 (suppl; abstr 10047). http://abstract.asco.org/176/AbstView_176_168148.html	5/15/10	11/15/11

C40503	A genome-wide association study (GWAS) of survival in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503. F Innocenti, K Owzar, C Jiang, AB Sibley, F Mulkey, L Carey, D Tripathy, B Schneider, W Barry, E Winer, Hudis, HL McLeod, MN Dickler. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session. J Clin Oncol 34, 2016 (suppl; abstr 538). http://abstract.asco.org/176/AbstView_176_166252.html	5/15/10	11/15/11
C40601	Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer. M Tanioka, C Fan, LA Carey, T Hyslop, B Pitcher, JS Parker, K Hoadley, NL Henry, S Tolaney, C Dang, IE Krop, L Harris, DA Berry, E Mardis, CM Perou, EP Winer, CA Hudis. San Antonio Breast Cancer Symposium (Dec 6-10, 2016, San Antonio, TX), accepted, oral presentation, #S3-05. http://www.abstracts2view.com/sabcs/view.php?nu=SABCS16L_1071	12/15/08	2/29/12
EBCTCG*	Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET). H Pan, RG Gray, C Davies, R Peto, JCS Bergh, KI Pritchard, M Dowsett, DF Hayes. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation. J Clin Oncol 34, 2016 (suppl; abstr 505). http://abstract.asco.org/176/AbstView_176_166053.html [*includes SWOG adjuvant trials data, including S8814, S8897]	n/a	n/a
NCIC MA17R	A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. P Goss, J Ingle, K Pritchard, H Muss, J Gralow, K Gelmon, T Whelan, K Strasser-Weippl, S Rubin, K Sturtz, A Wolff, E Winer, C Hudis, A Stopeck, JT Beck, J Salmon Kaur, K Whelan, D Tu, W Parulekar. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation. J Clin Oncol 34, 2016 (suppl; abstr LBA1). http://abstract.asco.org/176/AbstView_176_164642.html	11/15/98	8/31/02
NCIC MA17R	Patient reported outcomes from MA.17R: a randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 Years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. J Lemieux, PE Goss, WR Parulekar, JN Ingle, KI Pritchard, NJ Robert, H Muss, J Gralow, K Strasser-Weippl, MD Brundage, K Whelan, D Tu, TJ Whelan, American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation, plenary session; and meet the press session. J Clin Oncol 34, 2016 (suppl; abstr LBA506) http://abstract.asco.org/176/AbstView_176_168693.html [see also SCQOL committee]	11/15/98	8/31/02

**SWOG
PUBLICATIONS LIST
BREAST COMMITTEE
2015**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
Breast Manuscripts Published (2015)			
S0221	SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer. GT Budd, W Barlow, HCF Moore, T Hobday, JA Stewart, C Isaacs, M Salim, J Cho, K Rinn, K Albain, H Chew, GV Burton, TD Moore, G Srkalovic, BA McGregor, LE Flaherty, RB Livingston, DL Lew, JR Gralow, GN Hortobagyi. <u>Journal of Clinical Oncology</u> 33(1):58-64, 2015. PMID25422488; PMC4268253 http://www.ncbi.nlm.nih.gov/pubmed/25422488	11/01/03	1/15/12
S0230	Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. HCF Moore, JM Unger, K-A Phillips, F Boyle, E Hitre, D Porter, PA Francis, LJ Goldstein, HL Gomez, CS Vallejos, AH Partridge, SR Dakhil, AA Garcia, J Gralow, J Lombard, JF Forbes, S Martino, WE Barlow, CJ Fabian, L Minasian, FL Meyskens, RD Gelber, GN Hortobagyi, KS Albain. <u>New England Journal of Medicine</u> 372(10):923-932, 2015. PMID25738668; PMCID 4405231 http://www.ncbi.nlm.nih.gov/pubmed/25738668	10/1/03	6/1/11
C9741	Body mass index, PAM50 subtype, and outcomes in node-positive breast cancer patients receiving chemotherapy: results from CALGB 9741 (ALLIANCE). JA Ligibel, CT Cirincione, M Liu, M Citron, J Ingle, W Gradishar, S Martino, W Sikov, R Michaelson, E Winer, CA Hudis, D Berry, WT Barry. <u>Journal of the National Cancer Institute</u> 2015 Jun 25;107(9). pii: djv179. doi: 10.1093/jnci/djv179. Print 2015 Sep. PMID26113580; PMC4651106 http://www.ncbi.nlm.nih.gov/pubmed/26113580	7/1/198	3/31/99
C40603	Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast conserving surgery and breast conservation rates: Surgical results from CALGB 40603 (Alliance). M Golshan, CT Cirincione, WM Sikov, DA Berry, S Jasinski, TF Weisberg, G Somlo, C Hudis, E Winer, DW Ollila. <u>Annals of Surgery</u> , Sep;262(3): 434-439, 2015; 2015 Jul 28 [Epub ahead of print]. PMID26222764; PMC4710511 http://www.ncbi.nlm.nih.gov/pubmed/26222764	6/1/1	8/31/12
C40603	Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II-III triple-negative breast cancer: CALGB 40603 (Alliance). WM Sikov, DA Berry, CM Perou, B Singh, CT Cirincione, SM Tolaney, CS Kuzma, TJ Pluard, G Somlo, ER Port, M Golshan, JR Bellon, D Collyar, OM Hahn, LA Carey, C Hudis, EP Winer. <u>Journal of Clinical Oncology</u> 33(1):13-21, 2015. PMID25092775; PMC4268249	6/1/10	8/31/12

<http://www.ncbi.nlm.nih.gov/pubmed/25092775>

C49907	Social support and its implications in elderly, early-stage breast cancer patients in CALGB 49907 (Alliance A171301). A Jatoi, H Muss, JB Allred, HJ Cohen, K Ballman, JR Gralow, JO Hopkins, A Gajra, J Lafky, A Hurria. <u>Psychooncology</u> , 2015 May 20. doi: 10.1002/pon.3850. [Epub ahead of print]. PMID: 25994447; PMC – pending http://www.ncbi.nlm.nih.gov/pubmed/25994447	7/15/02	12/29/06
E1199	Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. JA Sparano, F Zhao, S Martino, JA Ligibel, EA Perez, T Saphner, AC Wolff, GW Sledge, Jr., WC Wood, NE Davidson. <u>Journal of Clinical Oncology</u> Jul 20;33(21):2353-2360, 2015; 2015 Jun 15 [Epub ahead of print]; PMID26077235; PMC4500829 http://www.ncbi.nlm.nih.gov/pubmed/26077235	12/1/99	1/8/02
ECOG PAACT-1	Prospective validation of a multiparameter assay in breast cancer. JA Sparano, RJ Gray, JA Zujewski, DF Makower, TJ Whelan, KS Albain, DF Hayes, CE Geyer Jr., EC Dees, EA Perez, JA Olson, Jr., MM Keane, C Santiago Vallejos Sologuren, RP Reddi, TF Goggins, IA Mayer, AM Brufsky, DL Toppmeyer, VG Kaklamani, JN Atkins, JL Berenberg, GW Sledge. <u>New England Journal of Medicine</u> , Nov 19; 373(21):2005-1420. 2015 Sep 27[Epub ahead of print]. PMID26412349; PMC4701034 http://www.ncbi.nlm.nih.gov/pubmed/26412349	5/1/06	8/20/10
IBCSG 24-02	Adjuvant ovarian suppression in premenopausal breast cancer. PA Francis, MM Regan, GF Fleming, I Láng, E Ciruelos, M Bellet, HR Bonnefoi, MA Climent, GA Da Prada, HJ Burstein, S Martino, NE Davidson, CE Geyer, BA Walley, R Coleman, P Kerbrat, S Buchholz, JN Ingle, EP Winer, M Rabaglio-Poretti, R Maibach, B Ruepp, A Giobbie-Hurder, KN Price, M Colleoni, G Viale, AS Coates, A Goldhirsch, RD Gelber, for the SOFT Investigators and the International Breast Cancer Study Group. <u>New England Journal of Medicine</u> Jan 29;372(5):436-446, 2015. PMID25495490; PMC4341825 http://www.ncbi.nlm.nih.gov/pubmed/25495490	8/15/03	4/30/10
N9831	Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the north central cancer treatment group N9831 adjuvant trastuzumab trial. EA Perez, EA Thompson, KV Ballman, SK Anderson, YW Asmann, KR Kalari, JE Eckel-Passow, AC Dueck, KS Tenner, J Jen, J-B Fan, XJ Geiger, AE McCullough, B Chen, RB Jenkins, GW Sledge, EP Winer, JR Gralow, MM Reinholz. <u>Journal of Clinical Oncology</u> Mar 1;33(7):701-708, 2015. PMID25605861;PMC4334774 http://www.ncbi.nlm.nih.gov/pubmed/25605861	7/1/00	4/30/05
N9831	The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. E Perez, F Baehner, S Butler, EA Thompson, A Dueck, F Jamshidian, D Cherbavaz, C Yoshizawa, S Shak, P Kaufman, N Davidson, J Gralow, Y Asmann, K Ballman. <u>Breast Cancer Research</u> , Oct 1;17(1):133, 2015. PMID26429296; PMC4589954 http://www.ncbi.nlm.nih.gov/pubmed/26429296	7/1/00	4/30/05

NCIC MA.21	Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. S Liu, J-A Chapman MJ Burnell, MN Levine, KI Pritchard, TJ Whelan, HS Rugo, KS Albain, EA Perez, S Virk, G Barry, D Gao, P O'Brien, LE Shepherd, TO Nielsen, KA Gelmon. <u>Breast Cancer Research and Treatment</u> Jan;149(2):439-448, 2015. PMID25552364; PMC – pending http://www.ncbi.nlm.nih.gov/pubmed/25552364		
NCIC MA.21	Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. AE Lohmann, JA Chapman, MJ Burnell, MN Levine, E Tsvetkova, KI Pritchard, KA Gelmon, P O'Brien, L Han, HS Rugo, KS Albain, EA Perez, TA Vandenberg, HI Chalhah, RP Sawhney, LE Shepherd, PJ Goodwin. <u>Breast Cancer Research and Treatment</u> Apr;150(3):605-611, 2015. PMID25833209; PMC – pending http://www.ncbi.nlm.nih.gov/pubmed/25833209		
NCIC MA.27	Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. V Stearns, JW Chapman, CX Ma, MJ Ellis, JN Ingle, KI Pritchard, GT Budd, M Rabaglio, GW Sledge, A Le Maitre, J Kundapur, PER Liedke, LE Shepherd, PE Goss. <u>Journal of Clinical Oncology</u> Jan 20;33(3):265-271, 2015. PMID5512454; PMC4289722 http://www.ncbi.nlm.nih.gov/pubmed/25512454	8/15/03	7/31/08

Breast Abstracts Published/Presented (2015)

S0221	A genome-wide association study identifies novel loci associated with taxane-related sensory neuropathy in breast cancer patients enrolled in a cooperative group clinical trial (SWOG S0221). LE Sucheston-Campbell, A Clay, WE Barlow, GT Budd, DO Stram, CA Haiman, L Yan, G Zirpoli, DL Hershman, KS Albain, DF Hayes, HCF Moore, TJ Hobday, JA Stewart, C Isaacs, M Salim, JR Gralow, GN Hortobagyi, RB Livingston, S Yao, C Jiang, X Sheng, K Owzar, DL Kroetz, CB Ambrosone. AACR 2015 Meeting (April 22, 2015, Philadelphia, PA) poster presentation; abstract number 5489. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=08a685c0-a2b2-4db4-9903-cc7fc127cdc4&cKey=df8207bf-9d1c-4348-8a5a-fdb5c1f70d92&mKey=%7b19573A54-AE8F-4E00-9C23-BD6D62268424%7d	11/01/03	1/15/12
S0226	Association between gene variants in SULT1A1 and UGT1A4 and disease outcomes in patients enrolled in SWOG S0226 and treated with anastrozole alone or in combination with fulvestrant for metastatic breast cancer. S Kadlubar, WE Barlow, RS Mehta, J Daniels, KS Albain, TA Vandenberg, SR Dakhil, NR Tirumali, DL Lew, JR Gralow, RB Livingston, GN Hortobagyi, DF Hayes, JM Rae. San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), accepted, poster, abst.# P3-07-64 http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1638	4/1/04	7/1/09

S0307	Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307 (NCT00127205). JR Gralow, WE Barlow, A Paterson, DL Lew, A Stopeck, DF Hayes, D Hershman, M Schubert, M Clemons, C Van Poznak, EC Dees, JN Ingle, C Falkson, AD Elias, M Messino, J Margolis, S Dakhil, H Chew, RB Livingston, GN Hortobagyi. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation; <u>J Clin Oncol</u> 33:5s, (suppl; abstr 503), 2015. http://abstracts.asco.org/156/AbstView_156_149911.html	11/15/05	2/1/10
S1207	Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-negative breast cancer: SWOG/NRG/Alliance S1207 (NCT01674140). M Chavez-MacGregor, WE Barlow, L Pusztai, MP Goetz, P Rastogi, PA Ganz, EP Mamounas, S Paik, H Bandos, J Gralow, DL Lew, GN Hortobagyi. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster discussion. <u>J Clin Oncol</u> 33:5s (suppl; abstr TPS637), 2015. http://abstracts.asco.org/156/AbstView_156_152660.html	9/3/13	n/a
S1207	Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-negative breast cancer: SWOG/NRG/Alliance S1207 (NCT01674140). M Chavez-MacGregor, WE Barlow, L Pusztai, MP Goetz, P Rastogi, PA Ganz, EP Mamounas, S Paik, H Bandos, J Gralow, DL Lew, GN Hortobagyi. San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), ongoing clinical trials category, accepted, poster, abstr.# OT1-03-11. http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1457	9/3/13	n/a
S8814	Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – transcriptome expression analysis of the phase III trial SWOG-8814. KS Albain, M Crager, WE Barlow, FL Baehner, A Bergamaschi, JM Rae, PM Ravdin, D Tripathy, JR Gralow, RB Livingston, CK Osborne, JN Ingle, KI Pritchard, NE Davidson, LA Carey, DB Cherbavaz, AP Sing, S Shak, GN Hortobagyi, DF Hayes. San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), accepted, oral presentation, abstr. # S3-02. http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1293	5/15/89	8/1/95
S8814	Successful whole transcriptome analysis of 25-year-old samples from the phase III trial SWOG-8814 by next generation sequencing (NGS): Standardized analytical methods for exploratory and validation studies. DB Cherbavaz, DF Hayes, K Qu, MR Crager, WE Barlow, AD Goddard, EM Beasley, J Jeong, F Collin, M-L Liu, JM Rae, PM Ravdin, D Tripathy, JR Gralow, RB Livingston, CK Osborne, JN Ingle, KI Pritchard, NE Davidson, LA Carey, AP Sing, FL Baehner, GN Hortobagyi, S Shak, KS Albain. San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), accepted, poster presentation, abstr.# P5-07-01. http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1295	5/15/89	8/1/95

C40503	Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). M Dickler, WT Barry, CT Cirrincione, M Ellis, ME Moynahan, H Rugo, B Schneider, D Tripathy, C Hudis, E Winer. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation. <i>J Clin Oncol</i> 33:5s (suppl; abstr 501), 2015. http://abstracts.asco.org/156/AbstView_156_143639.html	5/15/10	11/15/11
C40603	Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). WM Sikov, DA Berry, CM Perou, B Singh, CT Cirrincione, SM Tolaney, G Somlo, ER Port, TBN (ECOG), TBN (NSABP), TBN (NCCTG), M Golshan, JR Bellon, D Collyar, OM Hahn, LA Carey, CA Hudis, EP Winer. San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), oral, abstr. S2-05. http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1658	6/1/10	8/31/12
C40603	Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide on breast conservation rates: Surgical results from CALGB 40603 (Alliance). M Golshan, CT Cirrincione, DA Berry, WM Sikov, S Jasinski, G Somlo, EP Winer, C Hudis, DW Ollila for the Alliance for Clinical Trials in Oncology. American Surgical Association (April 23-25, 2015, San Diego, CA), oral presentation, abstr.3, 2015. http://meeting.americansurgical.org/abstracts/2015/3.cgi	6/1/1	8/31/12
C40603/40601	Impact of neoadjuvant therapy on breast conservation rates in triple- negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance). M Golshan, CT Cirrincione, D Berry, L Carey, W Sikov, NL Henry, G Somlo, E Port, E Winer, CA Hudis, D Ollila. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation. <i>J Clin Oncol</i> 33:5s(suppl; abstr 1007), 2015. http://abstracts.asco.org/156/AbstView_156_145808.html	6/1/1	8/31/12
ECOG PACCT-1	Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. M Zlobinsky Rubinstein, RJ Gray, JA Sparano, J Zujewski, TJ Whelan, KS Albain, DF Hayes, CE Geyer Jr., EC Dees, EA Perez, MM Keane, C Vallejos, TF Goggins, IA Mayer, A Brufsky, D Toppmeyer, VG Kaklamani, J Atkins, J Berenberg, GW Sledge. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session. <i>J Clin Oncol</i> 33:5s(suppl; abstr 533) 2015. http://abstracts.asco.org/156/AbstView_156_145430.html	5/1/06	8/20/10
ECOG PACCT-1	Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2/neu-negative, node-negative breast cancer: results of the TAILORx low risk registry. J Sparano, R Gray, J Zujewski, D Makower, T Whelan, KS Albain, DF Hayes, CE Geyer Jr., E Dees, EA Perez, M Keane, C Vallejos, TF Goggins, IA Mayer, A Brufsky, D Toppmeyer, VG Kaklamani, J Atkins, J Berenberg, GW Sledge. European Cancer Congress (ESMO) Annual Meeting, (Sept 25-29, 2015, Vienna, Austria), oral presentation, abstr. 5BA. http://www.europeancongress.org/Scientific-Programme/Abstract-search?abstractid=20456	5/1/06	8/20/10

ECOG PACCT-1	Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2/neu-negative, node-negative breast cancer: results of the TAILORx low risk registry. J Sparano, R Gray, J Zujewski, D Makower, T Whelan, KS Albain, DF Hayes, CE Geyer Jr., E Dees, EA Perez, M Keane, C Vallejos, TF Goggins, IA Mayer, A Brufsky, D Toppmeyer, VG Kaklamani, J Atkins, J Berenberg, GW Sledge. San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), accepted, poster, abst.# P2-08-01 http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_502	5/1/06	8/20/10
NSABP B-35	Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. RG Margolese, RS Cecchini, TB Julian, PA Ganz, JP Costantino, L Vallow, KS Albain, PW Whitworth, ME Cianfrocca, A Brufsky, HM Gross, GS Soori, JO Hopkins, L Fehrenbacher, K Sturtz, TF Wozniak, TE Seay, EP Mamounas, N Wolmark. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation. <i>J Clin Oncol</i> 33:5s, 2015 (suppl; abstr LBA500). http://abstracts.asco.org/156/AbstView_156_146144.html	7/1/03	6/15/06
NSABP B-35	Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. PA Ganz, RS Cecchini, TB Julian, RG Margolese, JP Costantino, LA Vallow, KS Albain, PW Whitworth, A Brufsky, HM Gross, GS Soori, JO Hopkins, L Fehrenbacher, K Sturtz, TF Wozniak, TE Seay, EP Mamounas, N Wolmark. San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), accepted, oral presentation, abstr. S6-05. [abstract link not available on website]	7/1/03	6/15/06
Z1071	Radiation use and field design in women with node positive breast cancer treated with preoperative systemic therapy and breast surgery including axillary dissection on a prospective clinical trial ACOSOG Z1071 [Alliance]. BG Haffty, LM McCall, KV Ballman, S McLaughlin, R Jagsi, DW Ollila, K Hunt, TA Buchholz, JC Boughey. ASTRO Annual Meeting (October 18-21, 2015, San Antonio, TX), oral presentation; <i>International Journal of Radiation Oncology, Biology, Physics</i> ; 93(3):Supplement S136, abstr 310, 2015. http://www.redjournal.org/article/S0360-3016(15)01055-X/abstract	12/1/09	5/29/12

**SWOG
PUBLICATIONS LIST
BREAST COMMITTEE
2014**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
Breast Manuscripts Published/Accepted (2014)			
S0102	A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. JR Gralow, WB Barlow, D Lew, K Dammann, G Somlo, KJ Rinn, SJ Vogel, L Wong, RL Livingston, GN Hortobagyi. <u>Breast Cancer Research and Treatment</u> , 143(2):351-358, 2014. PMID24352574; PMC3889983 http://www.ncbi.nlm.nih.gov/pubmed/24352574	5/1/01	1/1/04
S0221	Germline genetic variants in ABCB1 ABCC1, and ALDH1A1 and risk of hematological and gastrointestinal toxicities in a SWOG phase III trial S0221 for breast cancer. S Yao, LE Sucheston, H Zhao, G Zirpoli, WE Barlow, HCF Moore, GT Budd, DL Hershman, W Davis, GL Ciupak, JA Stewart, C Isaacs, TJ Hobday, M Salim, GN Hortobagyi, JR Gralow, RB Livingston, KS Albain, DF Hayes, CB Ambrosone. <u>The Pharmacogenomics Journal</u> , 14(3):241-247, 2014. PMID23999597; PMC3940691 http://www.ncbi.nlm.nih.gov/pubmed/23999597	11/01/03	1/15/12
S0500	SWOG S0500: circulating tumor cells and response to chemotherapy in metastatic breast cancer. JB Smerage, WE Barlow, GN Hortobagyi, EP Winer, B Leyland-Jones, G Srkalovic, S Tejwani, AF Schott, MA O'Rourke, DL Lew, JR Gralow, RB Livingston, DF Hayes. <u>Journal of Clinical Oncology</u> 32(31):3483-3489, 2014. PMID24888818; PMC4209100 http://www.ncbi.nlm.nih.gov/pubmed/24888818	10/1/06	3/15/12
S0800	Image registration for quantitative parametric response mapping of cancer treatment response. JL Boes, BA Hoff, N Hylton, MD Pickles, LW Turnbull, AF Schott, A Rehemtulla, R Chamberlain, TL Chenevert, CJ Galbán, CR Meyer, BD Ross. <u>Translational Oncology</u> 7(1):101-110, 2014. PMID24772213; PMC3998680 http://www.ncbi.nlm.nih.gov/pubmed/24772213	4/1/10	10/1/12
(Pending)	Promoting quality and evidence-based care in early-stage breast cancer follow-up. LN Henry, DF Hayes, SD Ramsey, GN Hortobagyi, WE Barlow, JR Gralow. <u>Journal of the National Cancer Institute</u> 106(4):dju034, 2014. PMID24627271 (commentary not within scope of Public Access Policy) http://www.ncbi.nlm.nih.gov/pubmed/24627271	n/a	n/a

C40101	Comparison of doxorubicin and cyclophosphamide (AC) versus single agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101 (Alliance). LN Shulman, DA Berry, C Cirincione, HP Becker, EA Perez, R O'Regan, S Martino, CL Shapiro, CJ Schneider, G Kimmick, HJ Burstein, L Norton, H Mus, CA Hudis, EP Winer, for the Alliance for Clinical Trials in Oncology. <i>Journal of Clinical Oncology</i> , 32(22):2311-2317, 2014. PMID24934787; PMC4105484 http://www.ncbi.nlm.nih.gov/pubmed/24934787	6/15/02	7/30/10
E2197/E1199	Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. S Adams, RJ Gray, S Demaria, L Goldstein, EA Perez, LN Shulman, S Martino, M Wang, VE Jones, TJ Saphner, AC Wolff, WC Wood, NE Davidson, GW Sledge, JA Sparano, SS Badve. <i>Journal of Clinical Oncology</i> 32(27):2959-2967, 2014. PMID:25071121; PMC4162494 http://www.ncbi.nlm.nih.gov/pubmed/25071121	12/1/99	1/8/02
E5103/E2100	Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. BP Schneider, L Li, F Shen, KD Miller, M Radovich, A O'Neill, RJ Gray, D Lane, DA Flockhart, G Jiang, Z Wang, D Lai, D Koller, JH Pratt, CT Dang, D Northfelt, E Perez, T Shenkier, M Cobleigh, ML Smith, E Railey, A Partridge, J Gralow, J Sparano, N Davidson, T Foroud, GW Sledge, Jr. <i>British Journal of Cancer</i> , 111(6):1241-1248, 2014, PMID25117820 http://www.ncbi.nlm.nih.gov/pubmed/25117820	11/1/02	5/26/04
IBCSG 24/25-02	Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. O Pagani, MM Regan, BA Walley, GF Fleming, M Colleoni, I Láng, H L Gomez, C Tondini, HJ Burstein, EA Perez, E Ciruelos, V Stearns, HR Bonnefoi, Silvana Martino, CE Geyer, Jr., G Pinotti, F Puglisi, D Crivellari, T Ruhstaller, EP Winer, M Rabaglio-Poretti, R Maibach, B Ruepp, A Giobbie-Hurder, KN Price, J Bernhard, W Luo, K Ribí, G Viale, AS Coates, RD Gelber, A Goldhirsch, PA. Francis, for the TEXT and SOFT Investigators and the International Breast Cancer Study Group. <i>New England Journal of Medicine</i> 371(2):107-118, 2014. PMID24881463; PMC4175521 http://www.ncbi.nlm.nih.gov/pubmed/24881463	8/15/03 8/15/03	4/30/10 11/30/07
MA.27B(NCIC)	Effects of adjuvant exemestane versus anastrozole on bone mineral density in women with early breast cancer: a companion study to NCIC CTG MA.27. P Goss, D Hershman, A Cheung, J Ingle, S Khosia, V Stearns, H Chalchal, K Rowland, H Muss, H Linden, J Scher, CR Elliott, T Crnjevic, JA Chapman, L Shepherd. <i>Lancet Oncology</i> 15(4):474-482, 2014. PMID:24636210 [also listed under SXQOL Committee] http://www.ncbi.nlm.nih.gov/pubmed/24636210	8/15/03	7/31/08
N9831	EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. H Cheng, K Ballman, M Vassilakopoulou, AC Dueck, MM Reinholz, K Tenner, J Gralow, C Hudis, NE Davidson, G Fountzilas, AE McCullough, B Chen, A Psyrrí, DL Rimm, EA Perez. <i>British Journal of Cancer</i> 111(6):1065-1071, 2014. PMID25117817 http://www.ncbi.nlm.nih.gov/pubmed/25117817	7/1/00	4/30/05

R9804	Web based pathology assessment in RTOG 98-04. WA Woodward, N Sneige, K Winter, HM Kuerer, C Hudis, E Rakovitch, BL Smith, LJ Pierce, I Germano, AT Pu, EM Walker, DL Grisell, JR White, B McCormick, for the Radiation Therapy Oncology Group (RTOG). <u>Journal of Clinical Pathology</u> 67(9):777-780, 2014. PMID24989024; PMC4145412 http://www.ncbi.nlm.nih.gov/pubmed/24989024	6/15/01	7/14/06
-------	--	---------	---------

Breast Abstracts Published/Presented/Accepted (2014)

S0221	Outcome of male patients and black patients enrolled in SWOG S0221, an intergroup chemotherapy study. GT Budd, WE Barlow, HCF Moore, TJ Hobday, JA Stewart, C Isaacs, M Salim, JK Cho, K Rinn, KS Albain, HK Chew, GV Burton, TD Moore, G Srkalovic, BA McGregor, LE Flaherty, RB Livingston, DL Lew, J Gralow, GN Hortobagyi. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 1016), 2014. http://abstracts.asco.org/144/AbstView_144_128157.html	11/01/03	1/15/12
S0230	Phase III Trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH Analog during Chemotherapy to Reduce Ovarian Failure in Early Stage, Hormone-Receptor Negative Breast Cancer: An International Intergroup Trial of SWOG, IBCSG, ECOG, CALGB (Alliance). HCF Moore, JM Unger, K-A Phillips, F Boyle, E Hitre, D Porter, P Francis, L Minasian, RD Gelber, LJ Goldstein, HL Gomez Moreno, CS Vallejos, AH Partridge, SR Dakhil, S Martino, W Barlow, CJ Fabian, FL Meyskens, GN Hortobagyi, KS Albain. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr LBA505), 2014. http://abstracts.asco.org/144/AbstView_144_129172.html	10/1/03	6/1/11
S0307	SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery (ClinicalTrials.gov Identifier: NCT00127205). JR Gralow, WE Barlow, A Paterson, DL Lew, A Stopeck, DF Hayes, D Hershman, M Schubert, M Clemons, C van Poznak, EC Dees, JN Ingle, CI Falkson, AD Elias, M Messino, J Margolis, S Dakhil, H Chew, RB Livingston, GN Hortobagyi. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 558), 2014. http://abstracts.asco.org/144/AbstView_144_129741.html	11/15/05	2/1/10
S0800	S0800: Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim with or without Bevacizumab in Treating Women with Inflammatory or Locally Advanced Breast Cancer (NCI CDR0000636131). ZA Nahleh, WE Barlow, AF Schott, DF Hayes, JR Gralow, E A Perez, WM Sikov, S Chennuru, H Mirshahidi, S Vidito, DL Lew, L Pusztai, RB Livingston, GN Hortobagyi. San Antonio Breast Cancer Symposium Annual Meeting (December 9-13, 2014, San Antonio, TX), poster presentation.	4/1/10	10/1/12

S0927	Omega-3-fatty acids for aromatase inhibitor-induced musculoskeletal symptoms in women with early stage breast cancer (SWOG S0927). D Hershman, J Unger, K Crew, S Dakhil, D Awad, H Greenlee, L Minasian, L Hansen, K Kaberle, DL Lew, JR Gralow, J Wade, F Meyskens, C Moinpour. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 9532), 2014. http://abstracts.asco.org/144/AbstView_144_130965.html	2/1/12	2/1/13
S1202	A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer: SWOG S1202. NL Henry, JM Unger, AF Schott, L Hansen, DL Lew, JL Wade, III, C Moinpour, GN Hortobagyi, FL Meyskens, Jr. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr TPS9662), 2014. http://abstracts.asco.org/144/AbstView_144_130393.html	5/15/13	n/a
C40601	Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). LA Carey, WT Barry, B Pitcher, KA Hoadley, MCU Cheang, IE Krop, NL Henry, DA Berry, CM Perou, EP Winer, CA Hudis. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 506), 2014. http://abstracts.asco.org/144/AbstView_144_129700.html	12/15/08	2/29/12
C40601	Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer. KA Hoadley, WT Barry, B Pitcher, JS Parker, MD Wilkerson, NL Henry, IE Krop, DA Berry, ER Mardis, CM Perou, EP Winer, CA Hudis, LA Carey on behalf of the Alliance for Clinical Trials in Oncology. San Antonio Breast Cancer Symposium Annual Meeting (December 9-13, 2014, San Antonio, TX), oral presentation.	12/15/08	2/29/12
C40603/ C150709	Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates with neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev) in triple-negative breast cancer (TNBC): Correlative studies from CALGB 40603/CALGB 150709 (Alliance). WM Sikov, WT Barry, KA Hoadley, BN Pitcher, B Singh, SM Tolaney, CS Kuzma, TJ Pluard, GSomlo, ER Port, M Golshan, DA Berry, OM Hahn, LA Carey, CM Perou, C Hudis, EP Winer. San Antonio Breast Cancer Symposium Annual Meeting (December 9-13, 2014, San Antonio, TX), oral presentation.	6/1/10	8/31/12

ECOG PACCT-1	Recurrence score and clinopathologic characteristics of TAILORx participants by race and ethnicity. JA Sparano, RJ Gray, TJ Whelan, KS Albain, DF Hayes, CE Geyer, Jr., EC Dees, EA Perez, JA Olson Jr., MM Keane, C Sologuren, RP Reddi, TF Goggins, IA Mayer, AM Brufsky, DL Toppmeyer, VG Kaklamani, JN Atkins, JL Berenberg, GW Sledge, Jr. ASCO Breast Cancer Symposium (September 4-6, 2014, San Francisco, CA), <u>Journal of Clinical Oncology</u> Vol 32, No 26_suppl, 2014: 36. http://meetinglibrary.asco.org/content/136701-151	5/1/06	8/20/10
IBCSG 24/25-02	Randomized comparison of adjuvant treatment with aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC): joint analysis of TEXT and SOFT. O Pagani, MM Regan, B Walley, G Fleming, M Colleoni, I Lang, H. Gomez, C Tondini, H Burstein, E Perez, EM Ciruelos, V Stearns, H Bonnefoi, S Martino, M Rabaglio, AS Coates, RD Gelber, A Goldhirsch, P Francis. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), "late breaking," scientific plenary session (oral). <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr LBA1), 2014. http://abstracts.asco.org/144/AbstView_144_129398.html	8/15/03 8/15/03	4/30/10 11/30/07
IBCSG 24-02	Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial. PA Francis, MM Regan, GF Fleming, I Lang, EM Ciruelos, M Bellet, H Bonnefoi, MA Climent, L Pavesi, HJ Burstein, S Martino, NE Davidson, CE Geyer, Jr., BA Walley, RE Coleman, P Kerbrat, M Rabaglio-Poretti, A. Coates, A Goldhirsch, RD Gelber. San Antonio Breast Cancer Symposium Annual Meeting (December 9-13, 2014, San Antonio, TX), oral presentation.	8/15/03	4/30/10
MA.21 (NCIC)	Prognostic associations of 25OH vitamin d in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high risk breast cancer (BC). AE Lohmann, J-A W Chapman, MJ Burnell, MN Levine, E Tsvetkova, KI Pritchard, KA Gelmon, P O'Brien, L Han, HS Rugo, KS Albain, EA Perez, TA Vandenberg, HI Chalhchal, RP Singh Sawhney, LE Shepherd, PJ Goodwin. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 504), 2014. http://abstracts.asco.org/144/AbstView_144_128900.html	11/1/02	4/6/05
MA.32 (NCIC)	Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl). MF Liebman, W Brien, WR Parulekar, KA Gelmon, LE Shepherd, JA Ligibel, DL Hershman, P Rastogi, IA Mayer, TJ Hobday, J Lemieux, AMThompson, KI Pritchard, TJ Whelan, S Mukherjee, HI Chalhchal, V Bernstein, V Stambolic, BE Chen, PJ Goodwin, from the NCIC CTG, Alliance, SWOG, NRG, ECOG, NSABP Cooperative Groups. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 542), 2014. http://abstracts.asco.org/144/AbstView_144_127505.html	9/15/10	1/22/13

**SWOG
PUBLICATIONS LIST
BREAST COMMITTEE
2013**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
Breast Manuscripts Published (2013)			
S0221	Supplement use during an intergroup clinical trial for breast cancer (S0221). G Zirpoli, P Brennan, CC Hong, S McCann, G Ciupak, W Davis, JM Unger, GT Budd, DL Hershman, HCF Moore, J Stewart, C Isaacs, T Hobday, M Salim, G Hortobagyi, J Gralow, K Albain, C Ambrosone. <u>Breast Cancer Research and Treatment</u> 137(3):903-913, 2013. PMID23306462;PMC3552360. http://www.ncbi.nlm.nih.gov/pubmed?term=Zirpoli%20GR%20supplement%20use	11/01/03	1/15/12
S0715	Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. D Hershman, J Unger, K Crew, L Minasian, C Moinpour, L Hansen, D Lew, L Fehrenbacher, J Wade, S Wong, G Hortobagyi, F Meyskens, K Albain. <u>Journal of Clinical Oncology</u> , 31(20):2627-2633, 2013. PMID23733756; PMC3699727 http://www.ncbi.nlm.nih.gov/pubmed/23733756	9/15/09	2/1/11
S1007	Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating OncotypeDx-guided management for women with breast cancer involving lymph nodes. S Ramsey, W Barlow, A Gonzalez-Angulo, S Tunis, L Baker, J Crowley, P Deverka, D Veenstra, GHortobagyi. <u>Contemporary Clinical Trials</u> 34(1):1-9, 2013. PMID:23000081; PMC3525786 http://www.ncbi.nlm.nih.gov/pubmed/23000081 (also reported under OCE Committee)	1/15/11	n/a
S1007	Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. R Thariani, NL Henry, SD Ramsey, DK Blough, B Barlow, JR Gralow, DL Veenstra. <u>Journal of Comparative Effectiveness Research</u> 2(3):325-234, 2013. PMID:24236631 http://www.ncbi.nlm.nih.gov/pubmed/24236631 (also reported under OCE Committee)	01/15/11	n/a
E2100	Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. BP Schneider, RJ Gray, M Radovich, F Shen, G Vance, L Li, G Jiang, KD Miller, JR Gralow, MN Dickler, MA Cobleigh, EA Perez, TN Shenkier, K Vang Nielsen, S Muller, A Thor, GW Sledge, JA Sparano, NE Davidson, SS Badve. <u>Clinical Cancer Research</u> 19(5):1281-1289, 2013. PMID23340303; PMC3594423 http://www.ncbi.nlm.nih.gov/pubmed/23340303	11/1/02	5/26/04

MA.17 (NCIC)	Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. PE Goss, JN Ingle, S Martino, NJ Robert, HB Muss, RB Livingston, NE Davidson, EA Perez, Y Chavarri-Guerra, Cameron DA, KL Pritchard, T Whelan, LE Shepherd, D Tu. <u>Annals of Oncology</u> 24(27):355-361, 2013. PMID23028039; PMC3551482 http://www.ncbi.nlm.nih.gov/pubmed/23028039	11/15/98	8/31/02
MA.27 (NCIC)	Exemestane versus anastrozole in postmenopausal women with early breast cancer. PE Goss, JN Ingle, JW Chapman, MJ Ellis, GW Sledge, GT Budd, DB Johnson, M Rabaglio, KI Pritchard, C Elliott, KA Gelmon, LE Shepherd. <u>Journal of Clinical Oncology</u> 31(11):1398-1404, 2013;PMID23358971; PMC3612593 http://www.ncbi.nlm.nih.gov/pubmed/23358971	8/15/03	7/31/08
N9831	Impact of c-MYC protein expression on outcome of patients with early stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (Alliance) N9831). AC Dueck, MM Reinholz, XJ Geiger, K Tenner, K Ballman, RB Jenkins, D Riehle, B Chen, AE McCullough, N Davidson, S Martino, GW Sledge, PA Kaufman, LA Kutteh, J Gralow, LN Harris, JN Ingle, WL Lingle, EA Perez. <u>Clinical Cancer Research</u> 19(20):5798-5807, 2013. PMID:23965903; PMC3805021 http://www.ncbi.nlm.nih.gov/pubmed/23965903	7/1/00	4/30/05
N9831	Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831. A Moreno-Aspitia, DW Hillman, SH Dyar, KS Tenner, J Gralow, P Kaufman, NE Davidson, JM Lafky, MM Reinholz, WL Lingle, LA Kutteh, WP Carney, AC Dueck, EA Perez. <u>Cancer</u> 119(15):2675-2682, 2013. PMID:23744760 http://www.ncbi.nlm.nih.gov/pubmed/23744760	7/1/00	4/30/05
N9831	Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Center Cancer Treatment Group N9831 trial. E Perez, A Dueck, A McCullough, B Chen, X Geiger, R Jenkins, W Lingle, N Davidson, S Martino, P Kaufman, L Kutteh, G Sledge, L Harris, J Gralow, M Reinholz. <u>Journal of Clinical Oncology</u> 31(17): 2115-2122, 2013. PMID23650412; PMC3731983 http://www.ncbi.nlm.nih.gov/pubmed/23650412	7/1/00	4/30/05
Z1071	Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JC Boughey , VJ Suman, EA Mittendorf , GM Ahrendt , LG Wilke, B Taback, AM Leitch, HM Kuerer, M Bowling, TS Flippo-Morton, DR Byrd, DW Ollila , TB Julian, SA McLaughlin, L McCall, WF Symmans, HT Le-Petross, BG Haffty , TA Buchholz , H Nelson, KK Hunt; Alliance for Clinical Trials in Oncology. <u>Journal of the American Medical Association</u> . 310(14):1455-1461, 2013. PMID:24101169 http://www.ncbi.nlm.nih.gov/pubmed/24101169	12/1/09	5/29/12

Breast Abstracts Published/Presented (2013)

S0221	S0221: Comparison of 2 schedules of paclitaxel as adjuvant therapy for breast cancer. GT Budd, W Barlow, HCF Moore, T Hobday, JA Stewart, C Isaacs, M Salim, JK Cho, K Rinn, K Albain, H Chew, GV Burton, TD Moore, G Srkalovic, B McGregor, L Flaherty, RB Livingston, D Lew, J Gralow, G Hortobagyi. <i>American Society of Clinical Oncology Annual Meeting</i> (May 31-June 4, 2013, Chicago, IL), submitted 1/21/13; oral presentation; <i>Journal of Clinical Oncology</i> 31(suppl; abstr CRA1008) http://abstracts2.asco.org/AbstView_132_108457.html	11/01/03	1/15/12
S0500	SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment. JB Smerage, WE Barlow, D Hayes, WP Winer, B Leyland-Jones, G Srkalovic, S Tejwani, AF Schott, MA O'Rourke, D Lew, JR Gralow, RB Livingston, GN Hortobagyi. San Antonio Breast Cancer Symposium (December 10-14, 2013, San Antonio, TX), oral presentation, abstr. S5-07. http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L_1097	10/1/06	3/15/12
S0812	Phase IIB randomized double-blind placebo-controlled biomarker modulation study of high dose vitamin D in premenopausal women at high-risk for breast cancer: SWOG S0812. KD Crew, DL Lew, D Hershman, S Refice, G Anderson, G Hortobagyi, GE Goodman, P Brown. San Antonio Breast Cancer Symposium ("TIPS"), (December 10-14, 2013, San Antonio, TX), poster presentation, abstr. OT3-3-02. (also under Prevention Committee) http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L_1326	11/1/2011	n/a
S1207	A phase III randomized, placebo-controlled clinical trial pending Activation evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-(HR) positive and Her2-neu-negative breast cancer: SWOG/NSABP S1207. M Chavez-MacGregor, WE Barlow, AM Gonzalez-Angulo, P Rastogi, EP Mamounas, PA Ganz, AF Schott, S Paik, DL Lew, H Bando, GN Hortobagyi. American Society of Clinical Oncology Annual Meeting (May 31-June 4, 2013, Chicago, IL), "Trials in Progress," general poster session. <i>Journal of Clinical Oncology</i> 31(suppl; abstr TPS657), 2013. http://abstracts2.asco.org/AbstView_132_118004.html		
C49907	The effect of renal function on outcomes in the adjuvant treatment of older women with breast cancer. An ancillary data study of CALGB/CTSU 49907 (Alliance). SM Lichtman, C Cirrincione, A Hurria, A Jatoi, J Gralow, HJ Cohen, HB Muss. American Society of Clinical Oncology Annual Meeting (May 31-June 4, 2013, Chicago, IL), poster discussion. <i>Journal of Clinical Oncology</i> 31(suppl; abstr 9515), 2013. http://abstracts2.asco.org/AbstView_132_111625.html	7/15/02	12/29/06

C40603	Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). W Sikov, D Berry, CM Perou , B Singh, C Cirrincione, S Tolaney, CS Kuzma,TJ Pluard, G Somlo, E Port, M Golshan, JR Bellon, D Collyar, OM Hahn, LA Carey, C Hudis, EP Winer. San Antonio Breast Cancer Symposium (December 10-14, 2013, San Antonio, TX), oral presentation, abstr. S5-01, 2013. http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L_458	6/1/10	8/31/12
E1199/E2197	Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. S Adams, R Gray, S Demaria, LJ Goldstein, EA Perez, LN Shulman, S Martino, NE Davidson, GW Sledge, JA Sparano, S Bavde. San Antonio Breast Cancer Symposium (December 10-14, 2013, San Antonio, TX), oral presentation, abstr. S1-07. http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L_906	12/1/99	1/8/02
N9831	The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831. EA Perez, SM Butler, AC Dueck, F Baehner, F Jamshidian, DB Cherbavaz, EA Thompson, S Shak, PA Kaufman, NE Davidson, J Gralow, Y Asmann, KV Ballman. <u>Journal of Clinical Oncology</u> 31(suppl;abstr 520, 2013. http://meetinglibrary.asco.org/content/114939-132	7/1/00	4/30/05

**SWOG
PUBLICATIONS LIST
BREAST COMMITTEE
2012**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
Breast Manuscripts Published (2012)			
S0226	Combination anastrozole and fulvestrant in metastatic breast in metastatic breast cancer. R Mehta, W Barlow, K Albain, T Vandenberg, S Dakhil, N Tirumali, DL Lew, DF Hayes, JR Gralow, R Livingston, GN Hortobagyi. <u>New England Journal of Medicine</u> 367(5):435-444, 2012. PMID22853014; PMC3951300 http://www.ncbi.nlm.nih.gov/pubmed/22853014	4/1/04	7/1/09
S0316	A prospective analysis of the influence of older age on physician decision-making when considering enrollment to breast cancer clinical trials (SWOG S0316). SH Javid, JM Unger, JR Gralow, CM Moinpour, AJ Wozniak, JW Goodwin, PN Lara, PA Williams, LF Hutchins, CC Gotay, KS Albain. <u>The Oncologist</u> , 17(9):1180-90, 2012. PMID22723506; PMC3448411 http://www.ncbi.nlm.nih.gov/pubmed/22723506	8/1/04	6/15/08
S0430	Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer. A Schott, B Barlow, K Albain, H Chew, J Wade, K Lanier, D Lew, D Hayes, J Gralow, R Livingston, G Hortobagyi. <u>The Oncologist</u> 17(2):179-87, 2012. PMID22267853; PMC3286166 http://www.ncbi.nlm.nih.gov/pubmed/22267853	8/15/05	9/1/07
S1007	Design of a clinical trial for testing the ability of a continuous marker to predict therapy benefit. WE Barlow. In J Crowley and A Hoering (Editors). <u>Handbook of Statistics in Clinical Oncology</u> , 3 rd Ed. CRC Press, 2012, Ch. 19, p. 293-304. [Book Chapter – PMCID or NIHMSID not applicable] (note: also listed under OCE Committee)	01/15/11	n/a
S1007	The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). W Wong, SD Ramsey, W Barlow, LP Garrison, DL Veenstra. <u>Contemporary Clinical Trials</u> , 33(6):1117-23, 2012. PMID2298189; PMC3486702 http://www.ncbi.nlm.nih.gov/pubmed/22981891 (also reported under OCE Committee)	01/15/11	n/a
C40101	Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary lymph nodes: Cancer and Leukemia Group B40101. LN Shulman, CT Cirincione, DA Berry, HP Becker, EA Perez, R O'Regan, S Martino, JN Atkins, E Mayer, CJ Schneider, G Kimmick, L Norton, H Muss, EP Winer, C Hudis. <u>Journal of Clinical Oncology</u> 30(33):4071-4076, 2012. PMID22826271; PMC3494835 http://www.ncbi.nlm.nih.gov/pubmed/22826271	6/15/02	7/30/10

E1199	Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. JA Sparano, M Wang, F Zhao, V Stearns, S Martino, J Ligibel, EA Perez, T Saphner, A Wolff, G Sledge, Jr., WC Wood, NE Davidson. <u>Journal of the National Cancer Institute</u> 104(5):406-14, 2012. PMID22250182; PMC3295746 http://www.ncbi.nlm.nih.gov/pubmed/22250182	12/1/99	1/8/02
E1199	Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. BP Schneider, F Zhao, M Wang, V Stearns, S Martino, V Jones, EA Perez, TJ Saphner, A Wolff, G Sledge, Jr., WC Wood, NE Davidson. <u>Journal of Clinical Oncology</u> 30(25):3051-3057, 2012. PMID22826271; PMC3494835 http://www.ncbi.nlm.nih.gov/pubmed/22826271		
E1199 E3189 E5188	Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. JA Sparano, M Wang, F Zhao, V Stearns, S Martino, JA Ligibel, EA Perez, T Saphner, AC Wolff, GW Sledge, WC Wood, J Fetting, NE Davidson. <u>Cancer</u> 118(23):5937-46, 2012. PMID:22926690;PMC3586227 http://www.ncbi.nlm.nih.gov/pubmed/22926690	12/1/99	1/8/02
E2197	Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. L Solin, R Gray, L Goldstein, A Recht, F Baehner, S Shak, S Badve, EA Perez, L Shulman S Martino, NE Davidson, GW Sledge, J Sparano. <u>Breast Cancer Research and Treatment</u> 134(2):683-692, 2012. PMID22547108; PMC3552372 http://www.ncbi.nlm.nih.gov/pubmed?term=solin%20%20E2197	7/1/00	4/30/05
EBCTCG/S8814	Comparisons between different polychemotherapy Regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, C Davies, J Godwin, R Gray, HC Pan, M Clarke, D Cutter, S Darby, P McGale, C Taylor, YC Wang, J Bergh, A DiLeo, K Albain, S Swain, M Piccart, K Pritchard. <u>Lancet</u> 379(9814):432-444, 2012. PMID: 22152853; PMC3273723 http://www.ncbi.nlm.nih.gov/pubmed/22152853	5/15/89	8/1/95
B-34 (NSABP)	Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34: a multicenter, placebo-controlled, randomized trial. AH Paterson, SJ Anderson, BC Lembersky, L Fehrenbacher, CI Falkson, KM King, LM Weir, AM Brufsky, S Dakhil, T Lad, L Baez-Diaz, JR Gralow, A Robidoux, EA Perez, P Zheng, CE Geyer, SM Swain, JP Costantino, EP Mamounas. <u>Lancet Oncology</u> , 13(7):734-742, 2012 . PMID22704583 http://www.ncbi.nlm.nih.gov/pubmed/22704583	11/102	3/31/04

N9831	Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER21-positivity criteria. EA Perez, AC Dueck, AE McCullough, MM Reinholz, KS Tenner, NE Davidson, J Gralow, LN Harris, LA Kutteh, DW Hillman, RB Jenkins, B Chen. <i>Journal of the National Cancer Institute</i> 104(2):159-162, 2012. PMID22138096; PMC3260130 http://www.ncbi.nlm.nih.gov/pubmed/22138096	7/1/00	4/30/05
-------	--	--------	---------

Breast Abstracts Published/Presented (2012)

S0715	SWOG S0715: randomized placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane induced neuropathy in women undergoing adjuvant breast cancer therapy. D Hershman, J Unger, K Crew, C Moinpour, L Minasian, L Hansen, D Lew, P O'Kane, J Wade, S Wong, G Hortobagyi, F Meyskens, K Albain. <i>American Society of Clinical Oncology 2012 Annual Meeting</i> (June 1-5, 2012, Chicago, IL), poster discussion; <i>J Clin Oncol</i> 30, 2012 (suppl; abstr 9018). http://abstract.asco.org/AbstView_114_95515.html [also listed under Cancer Survivorship Committee]	9/15/09	2/1/11
-------	--	---------	--------

S1200	Methods for standardizing true and sham acupuncture in a multicenter randomized trial to reduce joint symptoms related to aromatase inhibitors in women with early stage breast cancer (SWOG 1200). H Greenlee, KD Crew, J Capodice, A Jeffres, D Awad, J Unger, D Lew, JA Hartline, L Hansen, DL Hershman. <i>Society of Integrative Oncology (October 8-10, 2012, Albuquerque, NM)</i> , oral presentation. [also listed under Symptom Control/QOLCommittee] http://www.integrativeonc.org/index.php/component/option.com_dropbox/Itemid,200/view.dropbox/	3/27/12	
-------	---	---------	--

S1207	A phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-(HR) positive and Her2-neu negative breast cancer: SWOG/NSABP S1207. M Chavez-MacGregor, WE Barlow, AM Gonzalez-Angulo, P Rastogi, EP Mamounas, PA Ganz, AF Schott, S Paik, DL Lew, H Bandos, GN Hortobagyi. <i>San Antonio Breast Cancer Symposium (December 4-8, 2012, San Antonio, TX)</i> , submitted 6/12/12. [TIP format]; accepted, poster presentation – ongoing trials); <u>Cancer Research</u> suppl):570S abstr. OT2-2-04, 2012. http://www.sabcs.org/UserPortal/Documents/SABCS_2012_Abstract_Book.pdf 72(24	pending activation	
-------	---	--------------------	--

PAACT-1 ECOG	Patient-reported cognitive impairments among women with breast cancer randomized to hormonal therapy alone versus chemotherapy followed by hormonal therapy: results from the TAILORx trial (PAACT-1). LI Wagner, R Gray, G Sledge, T Whelan, JA Zujewski, D Hayes, C Geyer, EC Dees, J Sparano. <i>International Cognition and Cancer Taskforce Meeting</i> (March 15-17, 2012, Paris, France), poster presentation. http://www.canceropole-nordouest.com/fileadmin/user_upload/Mini-sites/ICCTF2012/programmecomplete/ICCTF2012.pdf	5/1/06	8/20/10
-----------------	--	--------	---------

**SWOG
PUBLICATIONS LIST
BREAST COMMITTEE
2011**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
BREAST MANUSCRIPTS PUBLISHED (2011)			
S0012	SWOG 0012: A phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant therapy for inflammatory and locally advanced breast cancer. GK Ellis, WE Barlow, JR Gralow, GN Hortobagyi, CA Russell, ME Royce, EA Perez, D Lew, RB Livingston. <u>Journal of Clinical Oncology</u> , 29(8):1014-1021, 2011. PMID21220618; PMC3024910 http://www.ncbi.nlm.nih.gov/pubmed?term=ellis%20gk%20SWOG%200012	5/1/01	12/1/05
S0215	SWOG S0215: A phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. RB Livingston, WE Barlow, JJ Kash, KS Albain, JR Gralow, D Lew, LE Flaherty, ME Royce, GN Hortobagyi. <u>Breast Cancer Research and Treatment</u> , 130(1):123-131, 2011. PMID21826527; PMC3513946 http://www.ncbi.nlm.nih.gov/pubmed/21826527	9/15/02	1/1/07
S0221	Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). L Sucheston, H Zhao, S Yao, G Zirpoli, S Liu, W Barlow, HCF Moore, G Budd, D Hershman, W Davis, G Ciupak, J Stewart, C Isaacs, T Hobday, M Salim, G Hortobagyi, J Gralow, R Livingston, K Albain, D Hayes, C Ambrosone. <u>Breast Cancer Research and Treatment</u> 130(3):993-1002, 2011. PMID21766209; PMC3532924 http://www.ncbi.nlm.nih.gov/pubmed/?term=sucheston+l+genetic+predictors	11/1/03	n/a
S9410 (C9344)	p53 expression in node-positive breast cancer patients: results from the cancer and leukemia group B 9344 trial (159905). JF Lara, AD Thor, LG Dressler, G Broadwater, IJ Bleiweiss, S Edgerton, D Cown, LJ Goldstein, S Martino, JN Ingle, IC Henderson, L Norton, EP Winer, CA Hudis, MJ Ellis, DA Berry, DF Hayes. <u>Clinical Cancer Research</u> 17(15):5170-5178, 2011. PMID21693655; PMC3149770 http://www.ncbi.nlm.nih.gov/pubmed?term=Lara%20JF%20p53	7/1/94	4/15/97
S9514 (ECOG) (EB193)	Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. RD Rao, MA Cobliegh, R Gray, ML Graham, L Norton, S Martino, GT Budd, JN Ingle, WC Wood. <u>Medical Oncology</u> 28 Suppl 1:S39-47, 2011. PMID20878269 http://www.ncbi.nlm.nih.gov/pubmed/20878269	12/1/95	11/1/99
S9623/Multiple	High dose chemotherapy with autologous stem cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. DA Berry, NT Ueno, MM Johnson, X Lei, J Caputo, S Rodenhuis, WP Peters, RC Leonard, WE Barlow, MS Tallman, J Bergh, UA Nitz, AM Gianni, RL Bassar, AR Zander, RC Coombes, H Roche, Y Tokuda, EGE de Vries, GN Hortobagyi, JP Crown, P Pedrazzoli, M Bregni, T Demirer. <u>Journal of Clinical Oncology</u> , 29(24):3214-3223, 2011. PMID21768471 (review article not within scope of Public Access Policy) http://www.ncbi.nlm.nih.gov/pubmed/21768471		

CTSU/B-30	Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. PA Ganz, SR Land, CE Geyer, RS Cecchini, JP Costantino, ER Pajon, L Fehrenbacher, JN Atkins, JA Polikoff, VG Vogel, JK Erban, RB Livingston, EA Perez, EP Mamounas, N Wolmark, SM Swain. <u>Journal of Clinical Oncology</u> 29(9):110-1116, 2011. PMID21300930; PMC3083866 http://www.ncbi.nlm.nih.gov/pubmed/21300930	11/1/02	3/31/04
C9741	Cancer and Leukemia Group B pathology committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. D Rimm, T Nielsen, S Jewel, D Rohrer, G Broadwater, F. Waldman, K Mitchell, B Singh, G Tsongalis, W Frankel, W Magliocco, J Lara, E His, I Bleiweiss, S Badve, B Chen, P Ravdin, R Schilsky, A Thor, D Berry. <u>Journal of Clinical Oncology</u> 2011. PMID21519016; PMC3107745 http://www.ncbi.nlm.nih.gov/pubmed/?term=rimm%20d%20pathology%20committee	7/1/98	3/31/99
MA.32 (NCIC)	Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. PJ Goodwin, V Stambolic, J Lemieux, BE Chen, WR Parulekar, KA Gelmon, DL Hershman, TJ Hobday, JA Ligibel, L Mayer, KI Pritchard, TJ Whelan, P Rastogi, LE Shepherd. <u>Breast Cancer Research and Treatment</u> 126(1):215-220, 2011. PMID20976543 http://www.ncbi.nlm.nih.gov/pubmed/?term=MA.32	9/15/10	1/22/13
N9831	C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the North Central Cancer Treatment Group N9831 adjuvant trastuzumab Trial. EA Perez, RB Jenkins, AC Dueck, AE Wiktor, PP Bedroske, SK Anderson, RP Kettering, WR Sukov, K Kanehira, B Chen, XJ Geiger, CA Andorfer, AE McCullough, NE Davidson, S Martino, GW Sledge, PA Kaufman, LA Kutteh, JR Gralow, LN Harris, JN Ingle, WL Lingle, MM Reinhold. <u>Journal of Clinical Oncology</u> 29(6):651-659, 2011. PMID21245420; PMC3056653 http://www.ncbi.nlm.nih.gov/pubmed/21245420	7/1/00	4/30/05
N9831	Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. EA Perez, VJ Suman, NE Davidson, JR Gralow, PA Kaufman, DW Visscher, B Chen, JN Ingle, SR Dakhil, J Zujewski, A Moreno-Aspitia, TM Pisansky, RB Jenkins. <u>Journal of Clinical Oncology</u> , 29(34):4491-7, 2011. PMID22042958; PMC3236650 http://www.ncbi.nlm.nih.gov/pubmed/22042958	7/1/00	4/30/05
N9831/ B-31	Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. EA Perez, EH Romond, VJ Suman, J-H Jeong, NE Davidson, CE Geyer Jr, S Martino, EP Mamounas, PA Kaufman, N Wolmark. <u>Journal of Clinical Oncology</u> 29(25):3366-3373, 2011. PMID21768458; PMC3164242 http://www.ncbi.nlm.nih.gov/pubmed/21768458	7/1/00	4/30/05
None	American Society of Clinical Oncology clinical practice guideline update on the role of bone modifying agents in metastatic breast cancer. CH Van Poznak, S Temin, GC Yee, NA Janjan, WE Barlow, JS Biermann, LD Bosserman, C Geoghegan, BE Hillner, RL Theriault, DS Zuckerman, JH Von Roenn. <u>Journal of Oncology Practice</u> 7(2):117-121, 2011. PMID 21343561; PMC3051857 http://www.ncbi.nlm.nih.gov/pubmed/21731520	n/a	n/a

None	Measuring the performance of markers for guiding treatment decisions. H Janes, MS Pepe, PM Bossuyt, WE Barlow. <u>Annals of Internal Medicine</u> 154(4):253-259, 2011. PMID21320940; PMC3085402 http://www.ncbi.nlm.nih.gov/pubmed?term=janes%20h%20measuring	n/a	n/a
------	---	-----	-----

None	American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone modifying agents in metastatic breast cancer. CH Van Poznak, S Temin, GC Yee, NA Janjan, WE Barlow, JS Biermann, LD Bosserman, C Geoghegan, BE Hillner, RL Theriault, DS Zuckerman, JH Von Roenn. <u>Journal of Clinical Oncology</u> 29(9):1221-1227, 2011. PMID21343561 (review article not within scope of Public Access Policy). http://www.ncbi.nlm.nih.gov/pubmed/21731520	n/a	n/a
------	---	-----	-----

BREAST ABSTRACTS PUBLISHED/PRESENTED (2011)

S0221	First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high risk early breast cancer. GT Budd, WE Barlow, HCF Moore, TJ Hobday, JA Stewart, C Isaacs, M Salim, JK Cho, K Rinn, KS Albain, HK Chew, GV Burton, TD Moore, G Srkalovic, BA McGregor, LE Flaherty, RB Livingston, D Lew, J Gralow, GN Hortobagyi. American Society of Clinical Oncology, 2011 annual meeting (June 4-8, 2011, Chicago, IL), oral presentation; <u>Journal of Clinical Oncology</u> 29:(suppl; abstr 1004), 2011. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=74054	11/01/03	n/a
-------	--	----------	-----

S0221	Effect of physician recommendation on multivitamin and antioxidant supplement use during chemotherapy in an adjuvant trial for breast cancer (SWOG S0221). G Zirpoli, PM Brennan, CC Hong, SC McCann, JM Unger, G Budd, D Hershman, J Stewart, C Isaacs, T Hobday, M Salim, G Hortobagyi, J Gralow, K Albain, D Hayes, C Ambrosone. Association for Cancer Research 102nd Annual Meeting (April 2-6, 2011, Orlando, FL), poster presentation.	11/1/03	n/a
-------	---	---------	-----

S0226	A phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: SWOG S0226. RS Mehta, WE Barlow, KS Albain, TA Vandenberg, SR Dakhil, NR Tirumali, DL Lew, DF Hayes, JR Gralow, RB Livingston, GN Hortobagyi. San Antonio Breast Cancer Symposium 2011 Meeting, oral presentation, abstract S1-1. http://www.abstracts2view.com/sabcs11/view.php?nu=SABCS11L_827	4/1/04	7/1/09
-------	---	--------	--------

S0927	SWOG S0927: a randomized placebo-controlled trial of omega-3-fatty acid for the control of aromatase inhibitor (AI)-induced musculoskeletal pain in women with early stage breast cancer. DL Hershman, J Unger, KD Crew, C Moinpour, L Minasian, L Hansen, D Lew, K Kaberle, J Wade, F Meyskens. San Antonio Breast Cancer Symposium 2011 Meeting, "Ongoing Trials" category; poster presentation, abstract OT2-07-02. http://www.abstracts2view.com/sabcs11/view.php?nu=SABCS11L_735	2/1/12	
-------	---	--------	--

S1007	SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor (HR)-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less. AM Gonzalez-Angulo, WE Barlow, JR Gralow, F Meric-Bernstam, DF Hayes, CM Moinpour, SD Ramsey, A Schott, D Sparks, KS Albain, GN Hortobagyi. ASCO 2011 annual meeting (June 4-8, 2011, Chicago, IL), "Trials in Progress" poster presentation; <u>Journal of Clinical Oncology</u> 29: (suppl; abstr TPS104), 2011. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76547	01/15/11	n/a
S1007	Incorporating comparative effectiveness research study endpoints into the treatment for positive node, endocrine responsive breast cancer (RxPONDER) study. SD Ramsey, WE Barlow, C Moinpour, AM Gonzalez-Angulo, GN Hortobagyi, DL Veenstra, LP Garrison, SR Tunis, LH Baker. ASCO 2011 annual meeting (June 4-8, 2011, Chicago, IL), "Trials in Progress" poster presentation; <u>Journal of Clinical Oncology</u> 29: (suppl; abstr TPS101), 2011. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82693	01/15/11	n/a
S1007	A randomized phase III clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor (HR)-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less: SWOG S1007. AM Gonzalez-Angulo, WE Barlow, JR Gralow, F Meric-Bernstam, DF Hayes, CM Moinpour, SD Ramsey, A Schott, D Sparks, KS Albain, GN Hortobagyi. San Antonio Breast Cancer Symposium 2011 Meeting, "Ongoing Trials" category, poster presentation, abstract OT1-03-01. http://www.abstracts2view.com/sabcs11/view.php?nu=SABCS11L_678	01/15/11	n/a
S1007	Designing a randomized trial to test an interaction of treatment and a continuous genomic assay. WE Barlow. International Society for Clinical Biostatistics 32 nd Annual Conference (August 21-25, 2011, Ottawa, Canada) invited oral presentation.	01/15/11	n/a
MA.32 (NCIC)	A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32) W Parulekar, BE Chen, C Elliott, LE Shepherd, K Gelmon, K Pritchard, T Whelan, IJ Ligibe, D Hershman, I Mayer, T Hobday, P Rastogi, P, J Lemieux, P Ganz, V Stambolic, PJ Goodwin. <u>Journal of Clinical Oncology</u> 29: (suppl; abstr TPS103), 2011. ASCO annual meeting, Trials in Progress, poster presentation. http://meetinglibrary.asco.org/content/82573-102		

**SWOG
PUBLICATIONS LIST
BREAST COMMITTEE
2010**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
BREAST MANUSCRIPTS PUBLISHED/PRESENTED (2010)			
S8814	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. KS Albain, W Barlow, S Shak, G Hortobagyi, RB Livingston, I-Tien Yah, P Ravdin, C Yoshizawa, F Baehner, N Davidson, G Sledge, E Winer, C Hudis, J Ingle, E Perez, K Pritchard, L Shepherd, JR Gralow, DC Allred, CK Osborne, DF Hayes. <u>Lancet Oncology</u> 11:55-65, 2010. PMID20005174; PMC3058239 http://www.ncbi.nlm.nih.gov/pubmed/20005174	5/15/89	8/1/95
S8814	In the interest of full disclosure – Author's reply (correspondence). KS Albain, WE Barlow. <u>Lancet Oncology</u> 11(4):315, 2010. PMID20359663 (correspondence) http://www.ncbi.nlm.nih.gov/pubmed/20359661	5/15/89	8/1/95
S8897	Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. S Yao, W Barlow, K Albain, JY Choi H Zhao, R Livingston, W Davis, J Rae, IT YEH, L Hutchins, P Ravdin, S Martino, A Lyss, CK Osborne, M Abeloff, G Hortobagyi, DF Hayes, C Ambrosone. <u>Clinical Cancer Research</u> 16(24):6169-6176, 2010. PMID21169260; PMC3058716 http://www.ncbi.nlm.nih.gov/pubmed/21169260	7/15/89	2/1/93
S8897	Manganese superoxide dismutase polymorphism treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. S Yao, W Barlow, K Albain, JY Choi, H Shao, R Livingston, W Davis, J Rae, IT Yah, L Hutchins, P Ravdin, S Martino, A Lyss, K Osborne, M Abeloff, G Hortobagyi, D Hayes. <u>Breast Cancer Treatment and Research</u> 124:433-439, 2010 PMID20309628; PMC2968705 http://www.ncbi.nlm.nih.gov/pubmed/20309628	7/15/89	2/1/93
S9114/C9082	Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. LB Marks, C Cirincione, TJ Fitzgerald, F Laurie, AS Glicksman, J Vredenburg, LR Prosnitz, EJ Shpall, M Crump, PG Richardson, MW Schuster, J Ma, BL Peterson, L Norton, S Seagren, I Henderson, DD Hurd, WP Peters; Cancer and Leukemia Group B; Southwest Oncology Group; National Cancer Institute of Canada Clinical Trials Group. <u>Int. J. Radiat. Oncol. Biol. Phys.</u> 76(5):1305-1313, 2010. PMID19747781; PMC3670136 http://www.ncbi.nlm.nih.gov/pubmed/19747781	12/15/91	6/1/98

S9313	Multiplexed assessment of the Southwest Oncology Group directed intergroup breast cancer trial S9313 by AQUA shows both high and low levels of HER2 are associated with poor outcome. M Harigopal, WE Barlow, G Tedeschi, PL Porter, IT Yeh, C Haskell, R Livingston, GN Hortobagyi, G Sledge, C Shapiro, J Ingle, DL Rimm, DF Hayes. <u>American Journal of Pathology</u> 176(4):1639-1647, 2010. PMC2843456; PMID20150438 http://www.ncbi.nlm.nih.gov/pubmed/20858857	3/15/94	5/1/97
S0012	Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). ML Slovak, V Bedell, D Lew, KS Albain, GK Ellis, RB Livingston, S Martino, EA Perez, G Hortobagyi, D Sher, W Stock. <u>Breast Cancer Res Treat</u> 119(2):391-398, 2010. PMID19851858 PMC3024910 http://www.ncbi.nlm.nih.gov/pubmed/19851858	5/1/01	12/1/05
B-30	Longer therapy and iatrogenic amenorrhea improve breast cancer survival. S Swain, JH Jeong, CE Geyer, JP Costantino, ER Pajon, LF Fehrenbacher, J Atkins, J Polikoff, VG Vogel, JK Erban, P Rastogi, RB Livingston, EA Perez, EP Mamounas, SR Land, PA Ganz, N Wolmark. <u>New England Journal of Medicine</u> , 362(22):2053-2065, 2010. PMID: 20519679; PMC2935316 http://www.ncbi.nlm.nih.gov/pubmed?term=ng%20k%20multivitamin	1/1/02	3/31/04
C49907	Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907:adherence companion study 60104. A Partridge, L Archer, A Kornblith, J Gralow, D Grenier, E Perez, A Wolff, X Wang, Kastrissios, D Berry, C Hudis, E Winer, H Muss. <u>Journal of Clinical Oncology</u> 28(14):2418-2422, 2010. PMC2881723; PMID20368559 http://www.ncbi.nlm.nih.gov/pubmed/20368559	7/15/02	12/29/06
MA.21 (NCIC)	Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. M Burnell, MN Levine, JW Chapman, V Bramwell, K Gelmon, B Walley, T Vandenberg, H Chalchal, KS Albain, EA Perez, H Rugo, K Pritchard, P O'Brien, LE Shepherd. <u>Journal of Clinical Oncology</u> 28(1):77-82, 2010. PMID19901117; PMC2799234. http://www.ncbi.nlm.nih.gov/pubmed/?term=albain+ks+epirubicin	11/1/02	4/6/05
N9831	HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. EA Perez, MM Reinholz, DW Hillman, KS Tenner, MJ Schroeder, NE Davidson, S Martino, G Sledge, LN Harris, J Gralow, AC Dueck, RP Kettering, J Ingle, WL Lingle, PA Kaufman, DW Visscher, RB Jenkins. <u>Journal of Clinical Oncology</u> 28(28):4307-4315, 2010. PMID20697084; PMC2954132 http://www.ncbi.nlm.nih.gov/pubmed/20697084	7/1/00	4/30/05

None	Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy. JA Sparano, ED Pisano, JR White, KK Hunt, EP Mamounas, EA Perez, GN Hortobagyi, JR Gralow, RL Comis. <i>Breast Cancer Research and Treatment</i> 120(2):273-284, 2010. PMID: 20024613 http://www.ncbi.nlm.nih.gov/pubmed/20024613	n/a	n/a
None	Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. KS Albain, L Carey, WJ Gradishar, JR Gralow, A Lipton, H Rugo, D Tripathy, S Peck, T Abair, M Pegram. <i>Clinical Breast Cancer</i> , 10(6): 421-439, 2010. PMID21147685 http://www.ncbi.nlm.nih.gov/pubmed?term=albain%20k%20global%20workshop	n/a	n/a

BREAST ABSTRACTS PUBLISHED/PRESENTED (2010)

S0430	Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC). AF Schott, D Lew, WE Barlow, KS Albain, HK Chew, JL Wade, KS Lanier, HM Linden, GN Hortobagyi, RB Livingston. Oral presentation, American Society for Clinical Oncology, 2010 Annual Meeting; <i>Journal of Clinical Oncology</i> 28:7s (suppl; abstr 1006), 2010; oral. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=41079	8/15/05	9/1/07
S8814	Potential tumor biologic causes of the racial survival disparity in ER-positive breast cancer adjuvant trials. KS Albain, WE Barlow, S Shak, GN Hortobagyi, DF Hayes. Oral presentation, American Society for Clinical Oncology, 2010 Annual Meeting; <i>Journal of Clinical Oncology</i> 28:7s (suppl; abstr 3640), 2010; oral http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=51657	5/15/89	8/1/95
C40302	Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study. H Burstein, W Barry, C Cirrincione, HK Chew, S Tolaney, D Lake, T Pluard, K Blackwell, E P Winer, C A Hudis. SABCS annual meeting; poster discussion; <i>Cancer Research</i> ; 70(24 suppl 2): abstr PD05-01, 2010. http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/70/24_MeetingAbstracts/PD05-01	9/1/06	7/14/10
E1199	Obesity at diagnosis is associated with inferior outcomes in hormone receptor positive breast cancer. JA Sparano, M Wang, S Martino, V Jones, EA Perez, T Saphner, AC Wolff, GW Sledge, WC Wood, J Fetting, NE Davidson. San Antonio Breast Cancer Symposium, abstr. #S2-1, general session, 2010. http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_500	12/1/99	1/8/02

N0733	N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer. P Haluska, MM Reinholz, AC Dueck, HM Linden, WL Lingle, AM Bernath, MC.Arbushites, H Youssoufian, HX Chen, EA Perez. ASCO annual meeting, "Trials in Progress," poster presentation; <u>J Clin Oncol</u> 28:15s:(suppl; abstr TPS129), 2010. http://meetinglibrary.asco.org/content/41264-74	8/15/08	6/8/12
N9831	c-MYC (MYC) protein expression and associations with trastuzumab benefit in early-stage, HER2+ breast cancer in context of the NCCTG adjuvant trial, N9831. MM Reinholz, AC Dueck, AE Wiktor, WL Lingle, RB Jenkins, NE Davidson, S Martino, PA Kaufman, LA Kutteh, GW Sledge, LN Harris, JR Gralow, X Geiger, EA Perez. San Antonio Breast Cancer Symposium, abst. #P2-09-08, poster session, 2010. http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_797	7/1/00	4/30/05
NCIC CTG MA.17	Quantitative protein and gene expression biomarkers of of tamoxifen and letrozole recurrence in the NCIC CTG MA.17 cohort. DC Sgroi, DM Finkelstein, L Shepherd, JN Ingle, DL Rimm, H Sasano, P Porter, M Pins, S Paik, A Ristimaki, KI Pritchard, D Tu, PE Goss. San Antonio Breast Cancer Symposium, abst. #P3-10-26, poster session, 2010. http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_1117		
NCIC CTG MA.27	Final analysis of NCIC CTG MA.27: a randomized phase III trial of exemestane versus anastrozole in post-menopausal women with hormone receptor positive primary breast cancer. PE Goss, JN Ingle, MJ Ellis, GW Sledge, GT Budd, M Ragaglio, K Gelmon, L Shepherd, KI Pritchard. San Antonio Breast Cancer Symposium, abstr. #S1-1, general session, 2010. http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_761	8/15/03	7/31/08

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
BREAST COMMITTEE
2009**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
BREAST MANUSCRIPTS PUBLISHED/PRESENTED (2009)			
** and *** S8814/8897 (2626)	Treatment quality and outcomes of African American versus Caucasian breast cancer patients: retrospective analysis of Southwest Oncology Group studies S8814/S8897. D. Hershman, J. Unger, WE Barlow, L Hutchins, S Martino, CK Osborne, RB Livingston, K Albain. <u>Journal of Clinical Oncology</u> 27(13):2157-2162, 2009. PMID: 19307504	5/15/89 7/15/89	8/1/95 2/1/93
S8814	Adjuvant chemotherapy and tamoxifen timing in postmenopausal, endocrine-responsive breast cancer. KS Albain, SJ Green, PM Ravdin, WB Farrar, GV Burton, SJ Ketchel, CD Cobau, EG Levine, JN Ingle, KI Pritchard, AS Lichter, DJ Schneider, MD Abeloff, IC Henderson, L Norton, D Lew, WE Barlow, RB Livingston, S Martino, CK Osborne, for the Breast Cancer Intergroup of North America. <u>Lancet</u> 374:2055-2063, 2009. PMID: 20004966	Breast	5/15/89 8/1/95
S8814 (2552)	Racial disparities in survival within sex-specific cancers but not other malignancies on Southwest Oncology Group trials. KS Albain, SJ Green, PM Ravdin, WB Farrar, GV Burton, SJ Ketchel, CD Cobau, EG Levine, JN Ingle, KI Pritchard, AS Lichter, DJ Schneider, MD Abeloff, IC Henderson, L Norton, D Lew, WE Barlow, RB Livingston, S Martino, CK Osborne, for The Breast Cancer Intergroup of North America. <u>Journal of the National Cancer Institute</u> , 101(14):984-92, 2009. PMID: 19584328	5/15/89	8/1/95
S8897 (2648)	Nitric oxide synthase (NOS3) variants and genes in related pathways in breast cancer treatment outcomes among women treated by CAF and CMF: Results from a Southwest Oncology Group Trial (S8897). JY Choi, WE Barlow, K Albain, CC Hong, JG Blanco, R Livingston, W Davis, JM Rae, IT Yeh, LF Hutchins, P Ravdin, S Martino, AP Lyss, K Osborne, M Abeloff, DF Hayes, CB Ambrosone. <u>Clinical Cancer Research</u> , 15(16):5258-66, 2009. PMID: 19671875	7/15/89	2/1/93
S8897 (2566)	Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for breast cancer: results from an ancillary study to Southwest Oncology Group Trial S8897 (INT-0102). CB Ambrosone, W Barlow, W Reynolds, RB Livingston, IT Yeh, JY Choi, W Davis JM Rae, L Tang, L Hutchins, PM Ravdin, S Martino, CK Osborne, M Abeloff, AP Lyss, DF Hayes, KS Albain. Not accepted by Nature Medicine 6/08; not accepted <u>JNCI</u> 10/08; <u>Journal of Clinical Oncology</u> , 27(30):4973-4979, 2009. PMID: 19752340	7/15/89	2/1/93

S9313 (2586)	Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. R Tubbs, WE Barlow, GT Budd, E Swain, P Porter, A Gown, IT Yeh, G Sledge, S Shapiro, J Ingle, C Haskell, K Albain, R Livingston, DF Hayes. <u>Journal of Clinical Oncology</u> 27:3881-3886, 2009. PMID: 19620488	3/15/94	5/1/97
N9831 (2593)	Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the North Central Cancer Treatment Group phase III trial, N9831. MY Halyard, TM Pisansky, AC Dueck, V Suman, L Pierce, L Solin, L Marks, N Davidson, S Martino, P Kaufman, L Kutteh, SR Dakhil, EA Perez. <u>Journal of Clinical Oncology</u> 27(16):2638-2644, 2009. PMID: 19349549	7/1/00	4/30/05

BREAST MANUSCRIPTS SUBMITTED/ACCEPTED (2009)

S9313 (2676)	Multiplexed assessment of the Southwest Oncology Group directed intergroup breast cancer trial S9313 by AQUA shows both high and low levels of HER2 are associated with poor outcome. M Harigopal, WE Barlow, G Tedeschi, PL Porter, IT Yeh, C Haskell, R Livingston, GN Hortobagyi, G Sledge, C Shapiro, J Ingle, DL Rimm, DF Hayes. Submitted to <u>Clinical Cancer Research</u> , 4/09; under review 5/26/09; not accepted 6/09; submitted to <u>American Journal of Pathology</u> 7/09.	3/15/94	5/1/97
S0012	SWOG 0012: A phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant therapy for inflammatory and locally advanced breast cancer. GK Ellis, WE Barlow, JR Gralow, GN Hortobagyi, CA Russell, ME Royce, EA Perez, D Lew, RB Livingston. (manuscript circulated to co-authors for review 6/30/09) Submitted to <u>Journal of Clinical Oncology</u> 12/17/09.	5/1/01	12/1/05
S0102	Southwest Oncology Group S0102: a phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer. JR Gralow, WB Barlow, D Lew, G Somlo, S Rivkin, S Taylor, L Wong, S Martino, S Green, RL Livingston, GN Hortobagyi. Submitted to <u>Journal of Clinical Oncology</u> , 11/09.	5/1/01	1/1/04
E2100	A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab (rumba QOL for VEGF) as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). L Wagner, M Wang, K Miller, NE Davidson, J Gralow, M Dickler, M Cobleigh, E Perez, T Shenkier, D Cella. Not accepted by <u>Journal of Clinical Oncology</u> 8/09; pending submission to <u>Cancer</u> .	11/1/02	5/26/04

BREAST ABSTRACTS PUBLISHED/PRESENTED (2009)

S0221 (2688)	Variants in the BRCA1/Fanconi-anemia repair pathway and taxane-induced neuropathy in SWOG directed intergroup study S0221. L Sucheston, H Zhao, S Yao, WE Barlow, DL Hershman, GT Budd, H Moore, W Davis, G Ciupak, J Stewart, C Isaacs, T Hobday, J Latreille, G Hortabagyi, J Gralow, R Livingston, K Albain, DF Hayes, CB Ambronsone. Poster presentation, 2009 San Antonio Breast Cancer Symposium, abstract #2001.	11/1/03	n/a
S0316	The influence of older age on physician and patient decision-making regarding enrollment to breast cancer clinical trials. SH Javid, JM Unger, JR gralow, CM Moinpour, AJ Wozniak, JW Goodwin, PN Lara, PA Williams, LF Hutchins, CC Gotay, KS Albain. Poster presentation, 2009 San Antonio Breast Cancer Symposium, abstract #3077.	8/1/04	6/15/08
S8814	Prediction of 10-year chemotherapy benefit and breast cancer-specific survival by the 21-gene recurrence (RS) assay in node-positive, ER-positive breast cancer – an update of SWOG-8814 (INT0100). Poster discussion, ("late breaking") San Antonio Breast Cancer Symposium, abstract #112, 2009.	5/15/89	8/1/95
E1199	Black race is associated with a worse outcome in patients with hormone receptor positive, HER2-normal breast cancer treated with adjuvant chemohormonal therapy. JA Sparano, M Wang, V Stearns, S Martino, V Jones, EA Perez, T Saphner, AC Wolff, GW Sledge, WC Wood, NE Davidson. General Session, 2009 San Antonio Breast Cancer Symposium, abstract #37.	12/1/99	1/8/02
E2197	Gene expression profiling of phenotypically-defined hormone Receptor positive breast cancer: evidence for increased transcriptional activity of the insulin growth factor receptor pathway and other pathways. JA Sparano, R Gray, LJ Goldstin, BH Childs, D Brassard, R Bugarini, S. Rowley, J Baker, S Shak, S Badve, FL Baehner, P Kenny, E Perez, LN Shulman, S Martino, GW Sledge, NE Davidson. Poster session, 2009 San Antonio Breast Cancer Symposium, abstract #5165.	11/1/98	1/21/00
N9831	Results of chemotherapy alone, with sequential or concurrent Addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. EA Perez, VJ Suman, NE Davidson, J Gralow, PA Kaufman, JN Ingle, SR Dakhil, JA Zujewski, TM Pisansky, RB Jenkins. General session, 2009 San Antonio Breast Cancer Symposium, abstract #80	7/1/00	4/30/05

* Presented

** Also reported under Cancer Survivorship Committee publications

*** Also reported under Health Disparities and Outcomes Committee

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2008
BREAST COMMITTEE**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED			
S8897/9342 (2385)	Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group (SWOG) protocol S8897. PA Ganz, MA Hussey, CM Moinpour, JM Unger, LF Hutchins, SR Dakhil, JK Giguere, JW Goodwin, S Martino, KS Albain. <u>Journal of Clinical Oncology</u> 26:1223-1230, 2008. PMID: 18227530 http://www.ncbi.nlm.nih.gov/pubmed?term=ganz%20pa%20late%20cardiac%20effects	7/15/89	2/1/93
S9626 (2357)	A phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group study 9626. JW Goodwin, SJ Green, CM Moinpour, JD Bearden III, JK Giguere, CS Jiang, SM Lippman, S Martino, KS Albain. <u>Journal of Clinical Oncology</u> , 26(10):1650-1656, 2008. PMID:18375894 http://www.ncbi.nlm.nih.gov/pubmed?term=goodwin%20j%20megestrol	4/15/98	5/1/00
S0338 (2547)	A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer. HK Chew, WE Barlow, K Albain, D Lew, A Gown, DF Hayes, J Gralow, GN Hortobagyi, R Livingston. <u>Clinical Breast Cancer</u> 8:511-515, 2008. PMID: 19073506; PMC3510680 http://www.ncbi.nlm.nih.gov/pubmed?term=chew%20h%20imatinib	6/15/04	12/15/05
B-33 B33	Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. EP Mamounas, JH Jeong, DL Wickerham, RE Smith, P Ganz, SR Land, A Eisen, L Fehrenbacher, W Farrar, J Atkins, ER Pajon, VG Vogel, JF Kroener, L Hutchins, JN Ingle, CE Geyer, JP Costantino, N Wolmark. <u>Journal of Clinical Oncology</u> 26(12):1965-1971. PMID18332472 http://www.ncbi.nlm.nih.gov/pubmed/18332472	05/01/01	02/18/04
E1199 (2498)	Weekly paclitaxel in the adjuvant treatment of breast cancer. JA Sparano, M Wang, S. Martino, V Jones, E Perez, TJ Saphner, AC Wolff, GW Sledge, WC Wood, NE Davidson. <u>New England Journal of Medicine</u> 358(16):1663-1671, 2008. PMC2743943; PMID: 18420499 http://www.ncbi.nlm.nih.gov/pubmed/18420499	12/1/99	1/8/02

E2100 (2695)	Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. BP Schneider, M Wang, M Radovich, GW Sledge, S Badve, A Thor, DA Flockhart, B Hancock, N Davidson, J Gralow, M Dickler, EA Perez, M Cobleigh, T Shenkier, S Edgerton, KD Miller. <u>Journal of Clinical Oncology</u> 27(8):1342, 2009. PMC2653128; PMID18824714. http://www.ncbi.nlm.nih.gov/pubmed/18824714	11/1/02	5/26/04
E2197	Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. LJ Goldstein, A O'Neill, JA Sparano, EA Perez, LN Shulman, S Martino, NE Davison. <u>Journal of Clinical Oncology</u> 26(25): 4092-4099, 2008. PMID18678836; PMC2654376 http://www.ncbi.nlm.nih.gov/pubmed/18678836	11/1/98	1/21/00
E2197	Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. LJ Goldstein, R Gray, S Badve, BH Childs, C Yoshizawa, S Rowley, S Shak, FL Baehner, PM Ravdin, NE Davidson, GW Sledge Jr, EA Perez, LN Shulman, S Martino, JA Sparano. <u>Journal of Clinical Oncology</u> 26(25):4063-4071, 2008. PMID18678838; PMC2654377 http://www.ncbi.nlm.nih.gov/pubmed/?term=goldstin+lj+prognostic+utility	11/1/98	1/21/00
E2197 (2568)	Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. SS Badve, FL Baehner, RP Gray, BH Childs, T Maddala, ML Liu, SC Rowley, S Shak, ED Perez, LJ Shulman, S Martino, NE Davidson, GW Sledge, LJ Goldstein, JA Sparano. <u>Journal of Clinical Oncology</u> 26(15): 2473-2481, 2008. PMID18487567 http://www.ncbi.nlm.nih.gov/pubmed?term=Badve%20SS%20ECOG	11/1/98	1/21/00
JMA17(NCIC)	Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. PE Goss, J Ingle, JL Pater, S Martino, NJ Robert, HB Ross, MJ Piccart, M Castiglione, LE Shepherd, KI Pritchard, RB Livingston, NE Davidson, L Norton, EA Perez, J Abrams, DA Camerson, MJ Palmer, D TU. <u>Journal of Clinical Oncology</u> 26(12):1948-1955, 2008. PMID18332475 http://www.ncbi.nlm.nih.gov/pubmed/18332475	11/15/98	8/31/02
JMA17 (NCIC)	Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. JN Ingle, D Tu, JL Pater, H Muss, S Martino, NJ Robert, MJ Piccart, M Castiglione, LE Shepherd, K Pritchard, R Livingston, N Davidson, L Norton, E Perez, J Abrams, D Cameron, MJ Palmer, PE Goss. <u>Annals of Oncology</u> 19(5):877-882, 2008. PMID18332043. http://www.ncbi.nlm.nih.gov/pubmed/18332043	11/15/98	8/31/02

JMA17 (NCIC)	Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. HB Muss, D Tu, JN Ingle, S Martino, N Robert, J Pater, T Whelan, M Palmer, M Piccart, LE Shepherd, KL Pritchard, Z He, PE Goss. <u>Journal of Clinical Oncology</u> , 26(12):1956-1964, 2008. PMID18332474 http://www.ncbi.nlm.nih.gov/pubmed/18332474	11/15/98	8/31/02
None (2589)	Recommendations for collection and handling of specimens from group breast cancer clinical trials, from onsite collection through shipping to the central bank. B Leyland-Jones, CB Ambrosone, M Ellis, R Enos, A Raji, M Pins, JA Zujewski, J Bartlett, S Hewitt, J Forbes, S Jewell. <u>Journal of Clinical Oncology</u> 26(34):5638-5644, 2008. PMC2651095; PMID18955459 http://www.ncbi.nlm.nih.gov/pubmed/18955459	n/a	

ABSTRACTS PRESENTED/PUBLISHED

**S0215 (2496)	Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. J Kash, WE Barlow, KS Albain, JR Gralow, D Lew, L Flaherty, ME Royce, GN Hortobagyi, RB Livingston. <u>Journal of Clinical Oncology</u> , 26(15S):49s, #1033, 2008. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33986	5/1/01	1/1/04
S9313 (2603)	Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous variable assessment. DL Rimm, M Harigopal, G Tedeschi, PL Porter, I-Tien Yeh, C Haskell, W Barlow, RB Livingston, G Hortobagyi, DF Hayes. <u>San Antonio Breast Cancer Symposium</u> , (poster presentation), abst. #704, 2008. http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_747	3/15/94	5/1/97
*CTS/B-30/ (2505)	NSABP B30: Definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. SM Swain, JH Jeong, CE Geyer, JP Costantino, ER Pajon, L Fehrenbacher, JN Atkins, JA Polikoff, VG Vogel, JK Erban, RB Livingston, E Perez, EP Eleftherios, P Mamounas, PA Ganz, SR Land, N Wolmark. <u>San Antonio Breast Cancer Symposium</u> , (oral presentation), abst. #75, 2008. http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_1017	1/1/02	3/31/04
CTS/B-30/ (2620)	NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of Adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node positive breast cancer. PA Ganz, SR Land, CE Geyer, JP Costantino, ER Pajon, L Fehrenbacher, JN Atkins, JAPolikoff, VG Vogel, JK Erban, RB Livingston, EA Perez, EP Mamounas, N Wolmark, SM Swain. <u>San Antonio Breast Cancer Symposium</u> , (general session), abst. #76, 2008. http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_852	1/1/02	3/31/04

* Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2007**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9313 (2257)	Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). HM Linden, CM Haskell, S Green, CK Osborne, GW Sledge, CL Shapiro, JN Ingle, D Lew, LF Hutchins, RB Livingston, S Martino. <u>Journal of Clinical Oncology</u> 25(6):656-661, 2007.	Breast	3/15/94	5/1/97
S9623 (2335)	Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. HCF Moore, SJ Green, JR Gralow, SI Bearman, D Lew, WE Barlow, C Hudis, AC Wolff, JN Ingle, HK Chew, AD Elias, RB Livingston, S Martino. <u>Journal of Clinical Oncology</u> 25(13):1677-1682, 2007.	Breast	7/1/96	2/15/01
S9632/S9832 (2363)	Impact of a peer-delivered telephone intervention for women experiencing a breast cancer recurrence. CC Gotay, CM Moinpour, JM Unger, CS Jiang, D Coleman, S Martino, BJ Parker, JD Bearden, S Dakhil, HM Gross, S Lippman, KS Albain. <u>Journal of Clinical Oncology</u> 25(15):2093-2099, 2007.	CC Breast		
ABSTRACTS PUBLISHED/PRESENTED				
*8814 (2427)	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-negative, ER-positive breast cancer (S8814, INT0100). K Albain, W Barlow, S Shak, G Hortobagyi, R Livingston, I Yeh, P Ravdin, C Yoshizawa, F Baehner, N Davidson, G Sledge, E Winer, C Hudis, J Ingle, E Perez, K Pritchard, L Shepherd, C Allred, K Osborne, D Hayes. <u>San Antonio Breast Cancer Symposium</u> #10, 2007.	Breast	5/15/89	8/1/95
*S0000 (2483)	Impact of new external research results in an ongoing trial. AK Darke, JL Hartline, P. Goodman. <u>Journal of the Society for Clinical Trials</u> , #144, p.115, 2007.	CC	7/25/01	6/24/04
S0012 (2341)	Screening for clonal hematopoiesis as a predictive marker for development of t-AML followign adjuvant thereapy for breast cancer (S0012). ML Slovak, V Bedell, D Lew, KS Albain, GK Ellis, R Livingston, S Martino, E Perez, D Sher, W Stock. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 25(18S):#11051, 2007.	Breast	5/01/01	12/01/05
S0102 (2414)	Expression of the microtubule-associated protein, tau, predicts improved survival, but not response, to a combination of docetaxel and vinorelbine in HER-2 negative metastatic breast cancer. JR Gralow, WE Barlow, AM Gown, LC Goldstein, PL Porter, IT Yeh, RB Livingston, DF Hayes. <u>San Antonio Breast Cancer Symposium</u> #2015, 2007.	Breast	5/1/01	1/1/04

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
E1199 2501	Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of intergroup trial E1199. JA Sparano, M Wang, S Martino, V Jones, E Perez, TJ Saphner, AC Wolff, GW Gledge, WC Wood, NE Davidson. <u>Journal of ClinicalOncology Proceedings of the American Society of Clinical Oncology</u> , abstract #516, 2007.	Breast	12/1/99	1/8/02
E2197	SS Badve, FL Baehner, R Gray, B Childs, T Maddala, S Rowley, S Shak, N Davidson, LJ Goldstein, J Sparano. Concordance of local and central laboratory hormone and HER2 receptor status in ECOG 2197. <u>Journal of Clinical Oncology</u> 25 (18S):21022, 2007.	Breast	11/1/98	1/21/00
N9831 (2382)	A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER-2 positive breast cancer. L Kutteh, T Hobday, A Jaffe, B Laplante, D Hillman, P Kaufman, N Davidson, S Martino, E Perez. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 25(18S):#579, 2007.	Breast	7/1/00	4/30/05

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2006**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9313 (2359)	p27Kip1 and cyclin e expression and breast cancer survival after treatment with adjuvant chemotherapy. PL Porter, WE Barlow, IT Yeh, MG Lin, XP Yuan, E Donato, GW Sledge, CL: Shapiro, JN Ingle, CM Haskell, KS Albain, JM Roberts, RB Livingston, DF Hayes. <u>Journal of the National Cancer Institute</u> 98(23):1723-1731, 2006.	Breast	3/15/94	5/1/97
ABSTRACTS PUBLISHED/PRESENTED				
* S8814/S8897	Treatment quality and outcome of african American vs. European American breast cancer patients: Retrospective analysis of Southwest Oncology Group Studies S8814/S8897. D Hershman, J Unger, W Barlow, L Hutchins, S Martino, M Abeloff, L Norton, R Livingstson, K Osborne, K Albain. <u>San Antonio Breast Cancer Symposium #3049, 2006.</u> http://www.abstracts2view.com/sabcs06/view.php?nu=SABCS06L_1034	5/15/89 7/15/89	8/1/95 2/1/93	
8897 (2360)	Pharmacogenetics and breast cancer treatment outcomes: results on oxidative stress-related genotypes (MPO, MnSOD) from a Southwest Oncology Group intergroup trial (INT-0102). CB Ambrosone, W Barlow, IT Yeh, DF Hayes, W Davis, JM Rae, LF Hutchins, R Livingston, P Ravdin, S Martino, K Osborne, M Abeloff, AP Lyss, K Albain. <u>Breast Cancer Research and Treatment</u> 100(Suppl 1):S18 (#37), 2006.	Breast	7/15/89	2/01/93
9410 (2277)	HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. DF Hayes, A Thor, L Dressler, D Weaver, G Broadwater, L Goldstein, S Martino, J Ingle, IC Henderson, D Berry. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 24(18S):#510, 2006.	Breast	7/1/94	4/15/97
S0012 (2233)	SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. GK Ellis, SJ Green, CA Russell, ME Royce, EA Perez, RB Livingston. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 24(18S):#LBA537, 2006.	Breast	5/1/01	12/1/05
S0338 (2234)	SWOG 0338: a phase II trial of imatinib mesylate in combination with capecitabine in metastatic breast cancer. H Chew, B Barlow, K Albain, D Lew, GT Budd, A Gown, J Gralow, RB Livingston. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 24(18S): #10529, 2006.	Breast	6/15/04	12/15/05

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
N9831	Adjuvant radiotherapy (RT) and trastuzumad in stage I-IIA breast cancer: toxicity data from North Central Treatment Group phase III trial N831. MY Halyard, TM Pisansky,, LJ Solin, LB Marks, LJ Pierce,, A Dueck, EA Perez. <u>Journal of Clinical Oncology</u> 24 (18S): 523, 2006.	Breast	7/1/00	4/30/05

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2005**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8851 (2423)	Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). NE Davidson, AM O'Neill, AM Vukov, CK Osborne, S Martino, DR White, MD Abeloff. <u>Journal of Clinical Oncology</u> 23(25):5973-5982, 2005.	Breast	8/1/89	2/1/94
8897 (2042)	Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer. treatment results of Intergroup protocol INT-0102. LF Hutchins, SJ Green, PM Ravdin, D Lew, S Martino, M Abeloff, AP Lyss, C Allred, SE Rivkin, CK Osborne. <u>Journal of Clinical Oncology</u> 23(33): 8313-8321, 2005.	Breast	7/15/89	2/1/93
8897 (2168)	Sequencing of tamoxifen and radiotherapy after breast conserving surgery in early-stage breast cancer. LJ Pierce, LF Hutchins, SR Green, DL Lew, JR Gralow, RB Livingston, CK Osborne, KS Albain. <u>Journal of Clinical Oncology</u> 23(1):24-29, 2005.	Breast	7/15/89	2/1/93
JMA17 (2208)	Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. PE Goss, JN Ingle, S Martino, NJ Robert, HB Muss, MJ Piccart, M Castiglione, D Tu, LE Shepherd, KI Pritchard, RB Livingston, NE Davidson, L Norton, EA Perez, JS Abrams, DA Cameron, MJ Palmer, JL Pater. <u>Journal of the National Cancer Institute</u> 97(17):1262-1271, 2005.	Breast	11/15/98	8/31/02
N9831 (2286)	Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. EH Romand, EA Perez, J Bryant, VJ Suman, CE Geyer, Jr, NE Davidson, E Tan-Chiu, S Martino, S Paik, PA Kaufman, SM Swain, TM Pisansky, L Fehrenbacher, LA Kutteh, VG Vogel, DW Visscher, G Yothers, RB Jenkins, AM Brown, SR Dakhil, EP Mamounas, WL Lingle, PM Klein, JN Ingle, N Wolmark. <u>New England Journal of Medicine</u> 353(16):1673-1684, 2005.	Breast	7/1/00	4/30/05
ABSTRACTS PUBLISHED/PRESENTED				
*9313 (2152)	Prognostic value of cell cycle regulators p27 and cyclin E: tissue microarray analysis of 1753 women enrolled in SWOG breast cancer trial 9313. PL Porter, W Barlow, IT Yeh, MG Lin, X Yuan, JN Ingle, CL Shapiro, GP Sledge, RB Livingston, DF Hayes. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 23(16S):5s	Breast	3/18/94	5/1/97

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
	(#507), 2005.			
S9623 (2205)	SWOG/Intergroup 9623: a phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (AHPCS) for primary breast cancer in women with >4 involved axillary lymph nodes. SI Bearman, S Green, J Gralow, W Barlow, C Hudis, A Wolff, J Ingle, G Hortobagyi, R Livingston, S Martino. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 23(16S):21s (#572), 2005.	Breast	7/1/96	2/15/01
S0102 (2228)	HIGH expression of the microtubule-associated protein, tau, strongly predicts improved progression free and overall survival in patients with metastatic HER-2 negative breast cancers treated with docetaxel and vinorelbine plus filgrastim. AM Gown, DO Treaba, LC Goldstein, PL Porter, JR Gralow, RB Livingston, S Tam, I-T Yeh, DF Hayes, W Barlow, D Lew. <u>Breast Cancer Research and Treatment</u> 94(Suppl 1):S50 (#1035), 2005.	Breast	5/1/01	1/1/04
*S0102 (2157)	SWOG S0102: a phase II study of docetaxel (DOC) and Vinorelbine (VNR) + filgrastim for HER-2 negative, stage IV breast cancer. J Gralow, S Green, D Lew, W Barlow, K Dammann, G Somlo, S Rivkin, S Taylor, L Wong, R Livingston. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 23(16S):20s (#567), 2005.	Breast	5/1/01	1/1/04
C9741 (2207)	Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less (DD) treatment: update by CALGB on breast cancer intergroup trial C9741 with ECOG, SWOG, & NCCTG. ML Citron, DA Berry C Cirincione, RB Livingston, W Gradishar, E Perez, H Muss, L Norton, E Winer, C Hudis. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 23(16S):33s (#620), 2005.	Breast	7/1/98	3/31/99
C9741 (2229)	Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. C Hudis, M Citron, D Berry, C Cirincione, W Gradishar, N Davidson, S Martino, R Livingston, J Ingle, E Perez, J Abrams, R Schilsky, M Ellis, H Muss, L Norton, E Winer. <u>Breast Cancer Research and Treatment</u> 94(Suppl 1):S20-S21 (#41), 2005.	Breast	7/1/98	3/31/99
E1199	Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Intergroup Trial E1199. JA Sparano, M Wang, S Martino, V Jones, E Perez, TJ Saphner, AC Wolff, WC Wood, NE Davidson. <u>Proceedings of the San Antonio Breast Cancer Symposium</u> , Abstract #48, 2005.	Breast	12/1/99	1/8/02

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
E2100 (2226)	A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). KD Miller, M Wang, J Gralow, M Dickler, MA Cobleigh, EA Perez, TN Shenkier, NE Davidson. <u>Breast Cancer Research and Treatment</u> 94(Suppl 1):S6 (#3), 2005.	Breast	11/1/02	5/26/04
N9831 (2227)	Exploratory analysis from NCCTG N9831: do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? EA Perez, VJ Suman, NE Davidson, PA Kaufman, S Martino, SR Dakhil, JN Ingle, RJ Rodeheffer, BJ Gersh, AS Jaffe. <u>Breast Cancer Research and Treatment</u> 94(Suppl 1):S96 (#2038), 2005.	Breast	7/1/00	4/30/05

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2004**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9314 (2070)	HER-2 amplification, HER-1 expression, and tamoxifen response in Estrogen Receptor-positive metastatic breast cancer: a Southwest Oncology Group study. G Arpino, SJ Green, DC Allred, D Lew, S Martino, CK Osborne, RM Elledge. <u>Clinical Cancer Research</u> 10:5670-5676, 2004.	Breast	9/1/93	12/15/95
9520 (2028)	A Southwest Oncology Group randomized phase II study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer. GH Lyman, SJ Green, PM Ravdin, CE Geyer Jr, CA Russell, SP Balcerzak, GT Budd, S Martino. <u>Breast Cancer Research and Treatment</u> 85:143-150, 2004.	Breast	12/15/95	10/1/97
ABSTRACTS PUBLISHED/PRESENTED				
*8814 (2150)	Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). K Albain, W Barlow, F O'Malley, K Siziopikou, IT Yeh, P Ravdin, D Lew, W Farrar, G Burton, S Ketchel, C Cobau, E Levine, J Ingle, K Pritchard, A Lichter, D Schneider, M Abeloff, IC Henderson, L Norton, D Hayes, S Green, R Livingston, S Martino, CK Osborne, DC Allred. <u>San Antonio Breast Cancer Symposium</u> Dec 2004 (late acceptances): abstract #37, http://www.abstracts2view.com/sabcs/sessionindex.php	Breast	5/15/89	8/1/95
S9632/S9832 (2225)	Enhancing well-being during breast cancer recurrence: preliminary findings from a phase III study. CC Gotay, CM Moinpour, CS Jiang, DP Ankerst, D Coleman, S Martino, B Taylor, J Bearden, S Dakhil, H Gross, KS Albain. <u>Breast Cancer Research and Treatment</u> 88(Suppl 1):S140 (#3080), 2004.	Breast	7/15/98	11/5/02

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2003**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7436 (1690)	Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes. 20-year results of a Southwest Oncology Group study. SE Rivkin, S Green, D Lew, JJ Costanzi, JW Athens, CK Osborne, CB Vaughn, S Martino. <u>Cancer</u> 97(1):21-29, 2003.	Breast	1/9/75	7/18/79
9061 (2137)	Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. MS Tallman, R Gray, NJ Robert, CF LeMaistre, CK Osborne, WP Vaughan, WJ Gradishar, TM Pisansky, J Fetting, E Paietta, HM Lazarus. <u>New England Journal of Medicine</u> 349(1):17-26, 2003.	Breast	1/15/92	8/3/98
9332 (1705)	Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). GW Sledge, D Neuberg, P Bernardo, JN Ingle, S Martino, EK Rowinsky, WC Wood. <u>Journal of Clinical Oncology</u> 21(4):588-592, 2003.	Breast	1/1/94	9/29/95
9410 (1651)	Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. IC Henderson, DA Berry, GD Demetri, CT Cirincione, LJ Goldstein, S Martino, JN Ingle, MR Cooper, DF Hayes, KH Tkaczuk, G Fleming, JF Holland, DB Duggan, JT Carpenter, E Frei III, RL Schilsky, WC Wood, HB Muss, L Norton. <u>Journal of Clinical Oncology</u> 21(6):976-983, 2003.	Breast	7/1/94	4/15/97
C9741 (2016)	Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. ML Citron, DA Berry, C Cirincione, C Hudis, EP Winer, WJ Gradishar, NE Davidson, S Martino, R Livingston, JN Ingle, EA Perez, J Carpenter, D Hurd, JF Holland, BL Smith, CI Sartor, EH Leung, J Abrams, RL Schilsky, HB Muss, L Norton. <u>Journal of Clinical Oncology</u> 21(8):1431-1439, 2003.	Breast	7/1/98	3/31/99

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

JMA17 (2113)	A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. PE Goss, JN Ingle, S Martino, NJ Robert, HB Muss, JM Piccart, M Castiglione, D Tu, LE Shepherd, KI Pritchard, RB Livingston, NE Davidson, L Norton, EA Perez, JS Abrams, P Therasse, MJ Palmer, JL Pater. <u>New England Journal of Medicine</u> 349(19):1793-1802, 2003.	Breast	11/15/98	8/31/02
-----------------	--	--------	----------	---------

ABSTRACTS PUBLISHED/PRESENTED

*8851 (1888)	Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: an Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). NE Davidson, A O'Neill, A Vukov, CK Osborne, S Martino, D White, M Abeloff. <u>Proc of the American Society of Clinical Oncology</u> 22:5 (#15), 2003.	Breast	8/1/89	2/1/94
-----------------	---	--------	--------	--------

*9061 (1886)	Phase III study of conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem cell transplantation in patients with stage II and III breast cancer at high risk of recurrence (INT 0121). M Tallman, R Gray, N Robert, C Osborne, W Vaughan, W Gradishar, T Pisansky, J Fetting, E Paietta, H Lazarus. <u>Proc of the American Society of Clinical Oncology</u> 22:6 (#19), 2003.	Breast	1/15/92	8/3/98
-----------------	--	--------	---------	--------

*9347 (1885)	Phase III comparison of tamoxifen versus tamoxifen with Ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer < 3 cm. NJ Robert, M Wang, D Cella, S Martino, D Tripathy, J Ingle, LJ Solin, WC Wood. <u>Proc of the American Society of Clinical Oncology</u> 22:5 (#16), 2003.	Breast	10/15/94	11/6/97
-----------------	---	--------	----------	---------

*E2197 (1887)	LVEF assessment of adjuvant doxorubicin/cyclophosphamide (AC) vs doxorubicin/docetaxel (AT) in early stage breast cancer: cardiac safety results of ECOG 2197. LJ Goldstein, A O'Neill, JA Sparano, EA Perez, LN Shulman, S Martino, AC Wolff, NE Davidson. <u>Proc of the American Society of Clinical Oncology</u> 22:19 (#73), 2003.	Breast	11/1/98	1/21/00
------------------	---	--------	---------	---------

Multiple Studies (2017)	Outcome of African Americans on Southwest Oncology Group (SWOG) breast cancer adjuvant therapy trials. KS Albain, JM Unger, LF Hutchins, SE Rivkin, S Martino, RB Livingston, CK Osborne. <u>Breast Cancer Research and Treatment</u> 82(Suppl 1):S12 (#21), 2003.	Breast		
-------------------------------	--	--------	--	--

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2002**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
ABSTRACTS PUBLISHED/PRESENTED				
8814 (1783)	Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup trial 0100 (SWOG-8814). KS Albain, SJ Green, PM Ravdin, CD Cobau, EG Levine, JN Ingle, KI Pritchard, DJ Schneider, MD Abeloff, L Norton, IC Henderson, D Lew, RB Livingston, S Martino, CK Osborne. <u>Proc of the American Society of Clinical Oncology</u> 21:37a (#143), 2002.	Breast	5/15/89	8/1/95
9313 (1786)	Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by cyclophosphamide (A->C) in breast cancer patients with 0-3 positive nodes (Intergroup 0137). CM Haskell, SJ Green, GW Sledge, CL Shapiro, JN Ingle, D Lew, S Martino, RB Livingston, K Osborne. <u>Proc of the American Society of Clinical Oncology</u> 21:36a (#142), 2002.	Breast	3/15/94	5/1/97
9314 (1893)	ErbB-2 amplification, ErbB-1 expression and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study. G Arpino, S Green, DC Allred, P Ravdin, D Lew, S Martino, CK Osborne, R Elledge. <u>Breast Cancer Research and Treatment</u> 76 (Suppl 1):S67, (#232), 2002.	Breast	9/1/93	12/15/95
9342 (1892)	Late cardiac effects of adjuvant CMF vs CAF in women with node negative breast cancer treated on SWOG 8897: initial results from SWOG 9342. PA Ganz, SJ Green, L Hutchins, S Martino, J Gralow, R Livingston, KS Albain. <u>Breast Cancer Research and Treatment</u> 76 (Suppl 1):S157, (#639), 2002.	Breast	2/15/97	OPEN

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2001**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8897 (2014)	Adjuvant therapy for very young women with breast cancer: need for tailored treatments. A Goldhirsch, RD Gelber, G Yothers, RJ Gray, S Green, J Bryant, S Gelber, M Castiglione-Gertsch, AS Coates. <u>Journal of the National Cancer Institute</u> Monographs No. 30:44-51, 2001.	Breast	7/15/89	2/1/93
9331 (1542)	Prediction of node negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: An Eastern Cooperative Oncology Group study (2192). DL Page, R Gray, DC Allred, LG Dressler, AK Hatfield, S Martino, NJ Robert, WC Wood. <u>American Journal of Clinical Oncology</u> 24(1):10-18, 2001.	Breast	11/15/93	10/5/95
ABSTRACTS PUBLISHED/PRESENTED				
*7827 (1758)	Adjuvant chemo and endocrine therapy for node positive breast cancer. 15 year results of Southwest Oncology Group (SWOG) study 7827. SE Rivkin, S Green, SJ Altman, JJ Costanzi, AB Cruz, C Giarritta, WR Jewell, RM O'Bryan. <u>Proc of the American Society of Clinical Oncology</u> 20:27a (#105), 2001.	Breast	7/16/79	8/1/89
7827 (1817)	Adjuvant chemo and endocrine therapy for node positive breast cancer. 15 year results of Southwest Oncology Group (SWOG) study 7827. SE Rivkin, S Green, SJ Altman, JJ Costanzi, AB Cruz, C Giarritta, WR Jewell, RM O'Bryan, CK Osborne. <u>Breast Cancer Research and Treatment</u> 69(3): 249, (#252), 2001.	Breast	7/16/79	8/1/89
*8814 (1720)	Overall survival after cyclophosphamide, adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor (+), node (+) breast cancer: new findings from phase III Southwest Oncology Group Intergroup trial S8814 (INT-0100). K Albain, S Green, P Ravdin, C Cobau, E Levine, J Ingle, K Pritchard, D Schneider, M Abeloff, L Norton, D Lew, S Martino, CK Osborne. <u>Proc of the American Society of Clinical Oncology</u> 20:24a (#94), 2001.	Breast	5/15/89	8/1/95
*9114 (1750)	Updated results of a prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/NCIC Ma-13. WP Peters, G Rosner, J Vredenburgh, E Shpall, M Crump, L Marks, C Cirrincione, D Hurd, L Norton. <u>Proc of the American Society of Clinical Oncology</u> 20:21a (#81), 2001.	Breast	12/1/91	5/29/98

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S9626 (1755)	Double blind phase III trial of placebo (P) vs. megestrol acetate (MA) 20 mg vs. MA 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: Initial results of Southwest Oncology Group S9626. JW Goodwin, SJ Green, S Giarritta, JK Giguere, K Hoelzer, J Bearden, RB Livingston, J Gralow, PA Ganz, S Martino, KS Albain. <u>Breast Cancer Research and Treatment</u> 69(3):292, (#462), 2001.	Breast	4/15/98	5/1/00

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2000**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9314 (1532)	Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR, and pS2 by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group study. RM Elledge, S Green, R Pugh, DC Allred, GM Clark, J Hill, P Ravdin, S Martino, CK Osborne. <u>International Journal of Cancer</u> 89:111-117, 2000.	Breast	9/1/93	12/15/95
9412 (1650)	Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. EA Stadtmauer, A O'Neill, LJ Goldstein, PA Crilley, KF Mangan, JN Ingle, I Brodsky, S Martino, HM Lazarus, JK Erban, C Sickles, JH Glick. <u>New England Journal of Medicine</u> 342(15):1069-1076, 2000.	Breast	7/1/94	12/23/97
ABSTRACTS PUBLISHED/PRESENTED				
*9514 (1662)	Fenretinide (FEN) vs placebo in postmenopausal breast cancer patients receiving adjuvant tamoxifen (TAM), an Eastern Cooperative Oncology Group Phase III Intergroup Trial (EB193, INT-0151). MA Cobleigh, R Gray, M Graham, L Norton, S Martino, GT Budd, JN Ingle, NE Davidson, WC Wood. <u>Proc of the American Society of Clinical Oncology</u> 19:86a (#328), 2000.	Breast	12/1/95	11/1/99
*9625 (1611)	Neoadjuvant doxorubicin, cyclophosphamide and G-CSF (AC+G) for locally advanced breast cancer (LABC), a Southwest Oncology Group phase II study. GK Ellis, SJ Green, RB Livingston, GT Budd, SE Rivkin, JK Giguere, DR Gandara, GR Weiss, S Martino. <u>Proc of the American Society of Clinical Oncology</u> 19:85a (#326), 2000.	Breast	4/15/97	8/15/98
*9632/9832 (1738)	An intervention to enhance well-being in women experiencing a breast cancer recurrence. C Gotay, C Moinpour, K Albain, S Martino, S Green, B Taylor, J Perotti, CA Coltman, Jr. <u>The Department of Defense Breast Cancer Research Program</u> 2:779, 2000.	Breast		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1999**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8923 (1300)	"Neo-FAC" (5-fluorouracil, doxorubicin and cyclophosphamide) for poor-prognosis stage IV breast cancer: a Southwest Oncology Group Phase II study. GK Ellis, S Green, RB Livingston, MJ Kraut, HI Pierce, JC Paradelo, SA Taylor, S Martino. <u>American Journal of Clinical Oncology</u> 22(5): 446-449, 1999.	Breast	2/15/90	6/1/92
9215 (1754)	Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. DL Fairclough, JH Fetting, D Cella, W Wonson, CM Moynour. <u>Quality of Life Research</u> 8:723-731, 1999.	Breast	9/15/92	4/29/93
ABSTRACTS PUBLISHED/PRESENTED				
*7436 (1536)	Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 20 year results of a Southwest Oncology Group study. SE Rivkin, S Green, D Lew, H Glucksberg, N Gad-el-Mawla, J Costanzi, B Hoogstraten, J Athens, T Maloney, C Osborne, C Vaughn, S Martino. <u>Proc of the American Society of Clinical Oncology</u> 18:69a (#259), 1999.	Breast	1/9/75	7/18/79
*8851 (1508)	Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). N Davidson, A O'Neill, T Habermann, CK Osborne, S Martino, D White, MD Abeloff. <u>Proc of the American Society of Clinical Oncology</u> 18:67a (#249), 1999.	Breast	8/1/89	2/1/94
*8897 (1588)	CMF versus CAF with or without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: Update of tamoxifen results. L Hutchins, S Green, D Lew, S Martino, M Abeloff, A Lyss, C Henderson, C Allred, S Dakhil, I Pierce, W Goodwin, J Caton, S Rivkin, R Chapman, K Osborne. <u>22nd Annual San Antonio Breast Cancer Symposium #1</u> , 1999.	Breast	7/15/89	2/1/93
*9114 (1548)	A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 0114/NCIC MA-13. W Peters, G Rosner, J Vredenburgh, E Shpall, M Crump, P Richardson, L Marks, C Cirrincione, W Wood, I Henderson, D Hurd, L Norton. <u>Proc of the American Society of Clinical Oncology</u> 18:1a (#2), 1999.	Breast	12/1/91	5/29/98

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*9412 (1524)	Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The 'Philadelphia' intergroup study (PBT-1). EA Stadtmauer, A O'Neill, LJ Goldstein, P Crifley, KF Mangan, JN Ingle, HM Lazarus, J Erban, C Sickles, JH Glick. <u>Proc of the American Society of Clinical Oncology</u> 18:1a (#1), 1999.	Breast	7/1/94	12/23/97

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1998**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8692 (1276)	Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study. CW Taylor, S Green, WS Dalton, S Martino, D Rector, JN Ingle, NJ Robert, GT Budd, JC Paradelo, RB Natale, JD Bearden, JA Mailliard, CK Osborne. <u>Journal of Clinical Oncology</u> 16(3):994-999, 1998.	Breast	8/1/87	7/15/95
8697 (1302)	Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. G Falkson, RS Gelman, KJ Pandya, CK Osborne, D Tormey, FJ Cummings, GW Sledge, MD Abeloff. <u>Journal of Clinical Oncology</u> 16(5):1669-1676, 1998.	Breast	11/15/87	2/13/91
8931 (1465)	Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: An intergroup study. JH Fetting, R Gray, DL Fairclough, TJ Smith, KA Margolin, ML Citron, M Grove-Conrad, D Cella, K Pandya, N Robert, IC Henderson, CK Osborne, MD Abeloff. <u>Journal of Clinical Oncology</u> 16(7):2382-2391, 1998.	Breast		
9248 (1284)	Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study. CE Geyer Jr, SJ Green, CM Moynour, J O'Sullivan, DK Goodwin, VA Canfield, FJ Meyers, CK Osborne, S Martino. <u>Breast Cancer Research and Treatment</u> 51:169-181, 1998.	Breast	6/1/93	2/1/94
9314 (1285)	HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study. RM Elledge, S Green, D Ciocca, R Pugh, DC Allred, GM Clark, J Hill, P Ravdin, J O'Sullivan, S Martino, CK Osborne. <u>Clinical Cancer Research</u> 4:7-12, 1998.	Breast	9/1/93	12/15/95
9314 (1339)	Heat shock proteins hsp27 and hsp70: Lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (A Southwest Oncology Group study). DR Ciocca, S Green, RM Elledge, GM Clark, R Pugh, P Ravdin, D Lew, S Martino, CK Osborne. <u>Clinical Cancer Research</u> 5:1263-1266, 1998.	Breast	9/1/93	12/15/95
Statistical Paper (1491)	Polychemotherapy for early breast cancer: an overview of the randomised trial. K Albain, J Crowley, S Green, S Martino, CK Osborne, PM Ravdin. <u>The Lancet</u> 352(9132):930-942, 1998.	Breast		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
*8897 (1372)	CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of intergroup trial INT 0102. L Hutchins, S Green, P Ravdin, D Lew, S Martino, M Abeloff, A Lyss, C Henderson, C Allred, S Dakhil, I Pierce, W Goodwin, J Caton, S Rivkin, R Chapman, K Osborne. <u>Proc of the American Society of Clinical Oncology</u> 17:1a (#2), 1998.	Breast	7/15/89	2/1/93
*8897 (1486)	A study of the late cardiac effects of two different adjuvant chemotherapy regimens in women with node negative breast cancer treated on SWOG 8897. PA Ganz. <u>Susan G. Komen Breast Cancer Foundation Symposium</u> ; Report of Grants Awarded in 1997:pg. 30, 1998.	Breast	7/15/89	2/1/93
9314 (1340)	Heat shock proteins hsp27 and hsp70 are not associated with clinical resistance to tamoxifen in breast cancer: A Southwest Oncology Group study. D Ciocca, S Green, R Elledge, G Clark, R Pugh, P Ravdin, D Lew, S Martino, CK Osborne. <u>Proc of the American Association for Cancer Research</u> 39:229 (#1568), 1998.	Breast	9/1/93	12/15/95
*9410 (1407)	Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). IC Henderson, D Berry, G Demetri, C Cirrincione, L Goldstein, S Martino, JN Ingle, MR Cooper, G Canellos, E Borden, G Fleming, JF Holland, S Graziano, J Carpenter, H Muss, L Norton. <u>Proc of the American Society of Clinical Oncology</u> 17:101a (#390a), 1998.	Breast	7/1/94	4/15/97
*9445 (1379)	Initial report of the SWOG biological correlative study of C-ERBB2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone. PM Ravdin, S Green, KS Albain, V Boucher, J Ingle, K Pritchard, L Shepard, N Davidson, DF Hayes, GM Clark, S Martino, CK Osborne, DC Allred. <u>Proc of the American Society of Clinical Oncology</u> 17:97a (#374), 1998.	Breast	2/1/95	10/1/98

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1997**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8312 (1236)	Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group phase III trial. CA Russell, SJ Green, J O'Sullivan, HE Hynes, GT Budd, JE Congdon, S Martino, CK Osborne. <u>Journal of Clinical Oncology</u> 15(7):2494-2501, 1997.	Breast	5/4/84	11/15/90
8807 (1177)	Improving breast self-examination compliance: A Southwest Oncology Group randomized trial of three interventions. CJ Strickland, P Feigl, C Upchurch, DK King, HI Pierce, PK Grevstad, JD Bearden III, M Dawson, WC Loewen, FL Meyskens Jr. <u>Preventive Medicine</u> 26:320-332, 1997.	CCR Breast	5/15/89	12/1/93
9314 (1194)	bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study. EM Elledge, S Green, L Howes, GM Clark, M Berardo, DC Allred, R Pugh, D Ciocca, P Ravdin, J O'Sullivan, S Rivkin, S Martino, CK Osborne. <u>Journal of Clinical Oncology</u> 15(5):1916-1922, 1997.	Breast	9/1/93	12/15/95
ABSTRACTS PUBLISHED/PRESENTED				
*8814 (1239)	Tamoxifen (T) versus cyclophosphamide, adriamycin® and 5-FU plus either concurrent or sequential T in postmenopausal, receptor(+), node(+) breast cancer: a Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100). K Albain, S Green, K Osborne, C Cobau, E Levine, J Ingle, K Pritchard, D Schneider, J O'Sullivan, E Hess, S Martino. <u>American Society of Clinical Oncology</u> 16:128a (#450), 1997.	Breast	5/15/89	8/1/95
9314 (1480)	ER and PGR by ligand binding assay compared with ER, PGR and PS2 by IHC in predicting response to tamoxifen in metastatic breast cancer. R Elledge, S Green, D Allred, G Clark, P Ravdin, S Martino, CK Osborne. <u>Breast Cancer Research and Treatment</u> 46:65 (#258), 1997.	Breast	9/1/93	12/15/95
*9332 (1281)	Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin + paclitaxel (A +T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. GW Sledge Jr, D Neuberg, J Ingle, S Martino, W Wood. <u>American Society of Clinical Oncology</u> 16:1a (#2), 1997.	Breast	1/1/94	9/29/95

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1996**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7436 (1317)	Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group study. SE Rivkin, S Green, B Metch, H Glucksberg, N Gad-el-Mawla, JJ Costanzi, B Hoogstraten, J Athens, T Maloney, CK Osborne, CB Vaughn. <u>Classic Papers and Current Comments</u> 1(1):85-93, 1996.	Breast	01/09/75	07/18/79
7827 (1095)	Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study. SE Rivkin, S Green, J O'Sullivan, AB Cruz, MD Abeloff, WR Jewell, JJ Costanzi, WB Farrar, CK Osborne. <u>Journal of Clinical Oncology</u> 14(1):46-51, 1996.	Breast	7/16/79	8/1/89
7827 (1318)	Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study. SE Rivkin, S Green, B Metch, AB Cruz, MD Abeloff, WR Jewell, JJ Costanzi, WB Farrar, JP Minton, CK Osborne. <u>Classic Papers and Current Comments</u> 1(1):120-128, 1996.	Breast	7/16/79	8/1/89
7827 (1319)	One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: A Southwest Oncology Group study. SE Rivkin, S Green, B Metch, WR Jewell, JJ Costanzi, SJ Altman, JP Minton, RM O'Bryan, CK Osborne. <u>Classic Papers and Current Comments</u> 1(1):129-135, 1996.	Breast	07/16/79	08/01/89
8814/8897 (1113)	Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: An analysis of two intergroup trials. KS Albain, SR Green, AS Lichter, LF Hutchins, WC Wood, IC Henderson, JN Ingle, J O'Sullivan, CK Osborne, S Martino. <u>Journal of Clinical Oncology</u> , 14(11):3009-3017, 1996.	Breast Women's Health		
ABSTRACTS PUBLISHED/PRESENTED				
8228 (1270)	HER-2/neu expression does not predict response to tamoxifen in er-positive metastatic breast cancer. R Elledge, S Green, D Ciocca, L Howes, R Pugh, G Clark, P Ravdin, J O'Sullivan, G Langone, CK Osborne. <u>Breast Cancer Research and Treatment</u> 41:289 (#518), 1996.	Breast	9/17/82	2/1/87

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
8692 (1130)	Phase 3, randomized, multi-center comparison of zoladex versus surgical ovariectomy in premenopausal patients with receptor positive metastatic breast cancer. CW Taylor, S Green, WS Dalton, S Martino, JN Ingle, NJ Robert, CK Osborne. <u>Proc Sixth International Congress on Anti-Cancer Treatment</u> (#120), 1996.	Breast	8/1/87	7/15/95
*9248 (1152)	A phase II trial of paclitaxel in patients with metastatic refractory carcinoma of the breast: A Southwest Oncology Group (SWOG) study. CE Geyer Jr, SJ Green, C Moynour, J O'Sullivan, D Goodwin, V Canfield, V Hamaski, S Martino. <u>American Society of Clinical Oncology</u> 15:107 (#92), 1996.	Breast	6/1/93	2/1/94
*9314 (1153)	bcl-2, p53, and response to tamoxifen in er-positive metastatic breast cancer. R Elledge, S Green, L Howes, M Berardo, DC Allred, G Clark, D Ciocca, CK Osborne, P Ravdin, J O'Sullivan, G Langone. <u>American Society of Clinical Oncology</u> 15:123 (#159), 1996.	Breast	9/1/93	12/15/95
*Multiple Studies (1228)	Interactions between very young age and prognostic factors for disease-free survival (DFS) in the presence or absence of adjuvant breast cancer therapy. KS Albain, DC Allred, GM Clark. <u>American Society of Clinical Oncology</u> 15:107 (#94), 1996.	Breast Women's Health		
*Multiple Studies (1155)	Metastatic breast cancer (MBC) in complete remission (CR): Observation versus CMFPTH maintenance: An ECOG randomized study. G Falkson, RC Gelman, KJ Pandya, CK Osborne, GW Sledge, MD Abeloff. <u>American Society of Clinical Oncology</u> 15:99 (#63), 1996.	Breast		
*Presented				

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1995**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8294 (INT-0011)) (1118)	Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. RM Elledge, R Gray, E Mansour, Y Yu, GM Clark, P Ravdin, CK Osborne, K Gilchrist, NE Davidson, N Robert, DC Tormey, DC Allred. <u>Journal of the National Cancer Institute</u> 87(16):1254-1256, 1995.	Breast	5/15/86	515/88
8313 (1012)	Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: An Intergroup study. GT Budd, S Green, RM O'Bryan, S Martino, MD Abeloff, JJ Rinehart, R Hahn, J Harris, D Tormey, J O'Sullivan, CK Osborne. <u>Journal of Clinical Oncology</u> 13(4):831-839, 1995.	Breast	4/20/84	6/15/90
Multiple Studies (1234)	Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. M Clarke, R Collins, J Godwin, R Gray, R Peto. <u>New England Journal of Medicine</u> 333(22):1444-1455, 1995.	Breast		
ABSTRACTS PUBLISHED/PRESENTED				
8692 (551)	A multi-center randomized trial of zoladex versus surgical ovariectomy in pre-menopausal patients with receptor positive metastatic breast cancer. CW Taylor, S Green, WS Dalton, S Martino, JN Ingle, NJ Robert, DJ Rector, CK Osborne. <u>Breast Cancer Research & Treatment</u> 37 (#19), 1995.	Breast	8/1/87	7/15/95
*8931 (1183)	CAF vs a 16 week multidrug regimen as adjuvant therapy for receptor-negative, node-positive breast cancer: An Intergroup study. J Fetting, R Gray, M Abeloff, B Fowble, T Smith, S Vail, G Durrani, L Eudey, J Henney, K Margolin, M Citron, C Osborne, C Henderson. <u>ASCO</u> 14:96 (#83), 1995.	Breast	7/15/90	4/29/93

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1994**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7827 (978)	Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study. SE Rivkin, S Green, B Metch, AB Cruz, MD Abeloff, WR Jewell, JJ Costanzi, WB Farrar, JP Minton, CK Osborne. <u>Journal of Clinical Oncology</u> 12(10):2078-2085, 1994.	Breast	7/16/79	8/1/89
8568 (1002)	Recruitment with high physiological doses of estradiol preceding chemotherapy: Flow cytometric and therapeutic results in women with locally advanced breast cancer-A Southwest Oncology Group study. CJ Fabian, BF Kimler, R McKittrick, CH Park, F Lin, L Krishnan, WR Jewell, CK Osborne, S Martino, LF Hutchins, LA Leong, S Green. <u>Cancer Research</u> 54:5357-5362, 1994.	Breast	3/4/86	11/15/90
8608 (876)	Phase II evaluation of mitoxantrone plus CIS-platinum in patients with advanced breast cancer: A Southwest Oncology Group study. JO Atiba, SJ Green, HE Hynes, CK Osborne, TP Miller, M Davidner. <u>Investigational New Drugs</u> 12:129-132, 1994.	Breast	2/16/87	8/1/89
8746 (882)	Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer. CK Osborne, MC Sunderland, JA Neidhart, PM Ravdin, MD Abeloff. <u>Annals of Oncology</u> 5:43-47, 1994.	Breast	9/1/88	8/15/92
8811 (886)	Phase II trial of 5-fluorouracil and high-dose folinic acid as first or second-line therapy for advanced breast cancer. KA Margolin, S Green, K Osborne, JH Doroshow, SA Akman, LA Leong, RJ Morgan, JW Raschko, G Somlo, L Hutchins, C Upchurch. <u>AJCO</u> 17(2):175-180, 1994.	Breast	09/01/88	11/15/90
8911 (1041)	Phase II trial of piroxantrone in metastatic breast cancer: A Southwest Oncology Group study. PM Ravdin, S Green, JH Doroshow, S Martino. <u>Investigational New Drugs</u> 12:333-336, 1994.	Breast	7/1/90	5/15/93
Multiple Studies (893)	Current trials and future directions of the Southwest Oncology Group (SWOG) Breast Cancer Committee. CK Osborne. <u>Cancer</u> 74(3):1135-1138, 1994.	Breast		

ABSTRACTS PUBLISHED/PRESENTED

8313 (1007)	Pitfalls in quality-of-life assessment: Lessons from a Southwest Oncology Group breast cancer clinical trial. K Hayden, C Moinpour, B Metch, P Feigl, R O'Bryan, S Green, K Osborne. <u>Nurse Investigator</u> 1(1):4, 1994.	Breast CCR	4/20/84	6/15/90
----------------	--	---------------	---------	---------

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*8814/8897 (962)	The influence of patient characteristics, socioeconomic (SES) factors, geography, and systemic risk on the use of breast sparing treatment in adjuvant breast cancer studies. A Lichter, S Green, K Albain, L Hutchins, S Martino. <u>ASCO</u> 13:62 (#51), 1994.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1993**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7827 (866)	One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: A Southwest Oncology Group study. SE Rivkin, S Green, B Metch, WR Jewell, JJ Costanzi, SJ Altman, JP Minton, RM O'Bryan, CK Osborne. <u>JCO</u> 11(9):1710-1716, 1993.	Breast	07/16/79	08/01/89
8313 (517)	Pitfalls in quality-of-life assessment: Lessons from a Southwest Oncology Group breast cancer clinical trial. KA Hayden, CM Moynour, B Metch, P Feigl, RM O'Bryan, S Green, CK Osborne. <u>Oncology Nursing Forum</u> 20(9):1415-1419, 1993.	Breast CCR	04/20/84	06/15/90

ABSTRACTS PUBLISHED/PRESENTED

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1992**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7436/7827 (777)	Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: A pilot study. KS Albain, S Green, M LeBlanc, S Rivkin, J O'Sullivan, CK Osborne. <u>Breast Cancer Research & Treatment</u> 22:273-284, 1992.	Breast Women's Health		
8228 (510)	Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. PM Ravdin, S Green, T Melink-Dorr, WL McGuire, C Fabian, RP Pugh, RD Carter, SE Rivkin, JR Borst, RJ Belt, B Metch, CK Osborne. <u>JCO</u> 10(8):1284-1291, 1992.	Breast	09/17/82	02/01/87
8294 (INT-0011) (512)	Chemotherapy versus observation in high-risk node-negative breast cancer patients. EG Mansour, L Eudey, DC Tormey, AH Shatila, CK Osborne, KW Gilchrist, MR Cooper, G Falkson. <u>Journal of the National Cancer Institute Monographs</u> 11:97-104, 1992.	Breast	05/15/86	05/15/88
8294 (INT-0011) (466)	Prognostic significance of S-Phase fraction in good risk node-negative breast cancer patients. GM Clark, MC Mathieu, MA Owens, LG Dressler, LE Eudey, DC Tormey, CK Osborne, KW Gilchrist, EG Mansour, MD Abeloff, WL McGuire. <u>JCO</u> 10(3):428-432, 1992.	Breast	07/15/89	05/15/88
8696 (INT-0076) (514)	Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. DC Allred, GM Clark, R Molina, AK Tandon, SJ Schnitt, KW Gilchrist, CK Osborne, DC Tormey, WL McGuire. <u>Human Pathology</u> 23(9):974-979, 1992.	Breast		
8696 (INT-0076) (533)	HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by presence in in situ carcinoma. DC Allred, GM Clark, AK Tandon, R Molina, DC Tormey, CK Osborne, KW Gilchrist, EG Monsour, M Abeloff, L Eudey, WL McGuire. <u>JCO</u> 10: 599-605, 1992.	Breast	07/01/88	07/01/89
8696 (INT-0076) (532)	Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: Preliminary analysis of an Intergroup study (INT-0076). LG Dressler, L Eudey, R Gray, DC Tormey, WL McGuire, KW Gilchrist, GM Clark, CK Osborne, EG Mansour, MD Abeloff. <u>JNCI Monographs</u> 11:167-172, 1992.	Breast	07/01/88	07/01/89

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
None (787)	Prognostic factors in clinical trials. S Dahlberg, PY Liu. <u>Breast Cancer Research and Treatment</u> 22: 193-196, 1992.	Breast		
Multiple Studies (894)	Recent and planned Southwest Oncology Group trials in operable breast cancer. GT Budd, S Green, CK Osborne, K Albain, L Dressler, S Rivkin, R O'Bryan, K Margolin, LF Hutchins. <u>Canadian Journal of Oncology</u> 3 (Suppl 2):47-53, 1992.	Breast		
ABSTRACTS PUBLISHED/PRESENTED				
7436/7827 (814)	Prognostic significance of lymphocyte counts (LC) in primary breast cancer (PBC). S Baumgaertel, R Livingston, S Rivkin, J O'Sullivan, S Green. <u>ASCO</u> 11:83 (#160), 1992.	Breast		
*8313 (818)	A comparison of CMFVP for one year to short term adriamycin based chemotherapy for patients with receptor-negative node positive operable breast cancer: An Intergroup study. R O'Bryan, S Green, J O'Sullivan, D Tesh, W Knight, R McDivitt, W Jewell, M Abeloff, CK Osborne. <u>ASCO</u> 11:61 (#71), 1992.	Breast CCR	04/20/84	06/15/90
*Multiple Studies (848)	A recursive partitioning and amalgamation (RPA) analysis of the Southwest Oncology Group node ⁺ adjuvant CMFVP data base: Four distinct prognostic groups are described by age, ER and number of nodes. K Albain, S Rivkin, S Green, M LeBlanc, CK Osborne. <u>ASCO</u> 11:57 (#53), 1992.	Breast		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
8811 (412)	Treatment of advanced breast cancer with 5-FU and high dose folinic acid. K Margolin, J Doroshow, S Green, S Akman, L Leong, RJ Morgan, J Raschko, G Somlo, L Hutchins, CK Osborne. <u>ASCO</u> 10:59 (#110), 1991.	Breast	09/01/88	11/15/90

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1990**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8294 (314)	Adjuvant therapy in node-negative breast cancer. It is necessary for all patients. An Intergroup study. EG Mansour, L Eudey, AH Shatila, DC Tormey, CK Osborne, KW Gilchrist, MR Cooper, R Gray, G Falkson. <u>Adjuvant Therapy of Cancer VI</u> , Sydney E. Salmon, (Ed.), W. B. Saunders Company, pp. 174-189, 1990.	Breast	05/15/86	05/1/5/88
ABSTRACTS PUBLISHED/PRESENTED				
7436/7827 (351)	Age < 35 years is an adverse prognostic feature in premenopausal node-positive breast cancer patients (PTS) in Southwest Oncology Group studies. K Albain, S Green, S Rivkin, K Osborne. <u>ASCO</u> 9:35 (#132), 1990.	Breast		
*7827 (352)	Adjuvant combination chemotherapy (CMFVP) vs tamoxifen (TAM) vs CMFVP+TAM for postmenopausal women with ER ⁺ operable breast cancer and positive axillary lymph nodes: An Intergroup study. S Rivkin, S Green, B Metch, A Cruz, R McDivitt, W Knight, J Glick, CK Osborne. <u>ASCO</u> 9:24 (#87), 1990.	Breast	07/16/79	08/01/89
8228 (354)	Correlation between progesterone receptor (PgR) and response to tamoxifen in patients (PTS) with estrogen receptor (ER) positive newly diagnosed metastatic breast cancer: A prospective Southwest Oncology Group study. T Melink, S Green, B Metch, W McGuire, G Clark, C Fabian, R Pugh, B Trantum, J Hill, CK Osborne. <u>ASCO</u> 9:53 (#202), 1990.	Breast	09/17/82	02/01/87
*8516/8819	Prognostic significance and clinical-pathological correlations of cell-cycle kinetics measured by Ki-67 immunocytochemistry in axillary node-negative carcinoma of the breast. RW Brown, DC Allred, GM Clark, AK Tandon, WL McGuire. <u>Breast Cancer Research and Treatment</u> 16:192 (#191), 1990.	Breast		
*8696 (369)	DNA flow cytometry measurements are prognostic for the time to recurrence in node-negative breast cancer: An Eastern Cooperative Group (ECOG) Intergroup study. LG Dressler, L Eudey, R Gray, DC Tormey, WL McGuire, GM Clark, CK Osborne, KW Gilchrist, EG Mansour, MD Abeloff. <u>ASCO</u> 9:22 (#81), 1990.	Breast	07/01/88	07/01/89
8696 (INT-0011)	Immunocytochemical analysis of HER-2/neu oncogene expression in in situ and invasive breast carcinoma: evaluation of pathological characteristics and biological significance. DC Allred, GM Clark, R Molina, AK Tandon, CK Osborne, DC Tormey, KW Gilchrist, WL McGuire. <u>Modern Pathology</u> 3(1):34, 1990.	Breast	07/01/88	07/01/89

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*Multiple Studies (380)	Immunocytochemical evaluation of HER-2/neu oncogene expression in different evolutionary stages of breast carcinoma and correlation with clinical pathological characteristics. DC Allred, GM Clark, R Molina, AK Tandon, SJ Schnitt, CK Osborne, DC Tormey, KW Gilchrist, WL McGuire. <u>ASCO</u> 9:23 (#83), 1990.	Breast		
*Multiple Studies (381)	HER-2/neu expression identified a group of node-negative breast cancer patients at high risk for recurrence. D Allred, G Clark, A Tandon, R Molina, D Tormey, CK Osborne, K Gilchrist, R Gray, E Mansour, M Abeloff, W McGuire. <u>ASCO</u> 9:23 (#85), 1990.	Breast		
None (383)	A new model for estimating S-phase fraction in node-negative breast cancer patients. GM Clark, MA Owens, LG Dressler, DC Tormey, CK Osborne, KW Gilchrist, R Gray, E Mansour, M Abeloff, WL McGuire. <u>AACR</u> 31:184 (#1094), 1990.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1989**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7436	Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group study. SE Rivkin, S Green, B Metch, H Glucksberg, N Gad-el-Mawla, JJ Costanzi, B Hoogstraten, J Athens, T Maloney, CK Osborne, CB Vaughn. <u>JCO</u> 7(9): 1229-1238, 1989.	Breast	01/09/75	07/18/79
8294	Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An Intergroup study. EG Mansour, R Gray, AH Shatila, CK Osborne, DC Tormey, KW Gilchrist, MR Cooper, G Falkson. <u>NEJM</u> 320(8):485-490, 1989.	Breast	05/15/86	05/15/88
8571	Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group study. GK Ellis, S Green, S Schulman, BL Trantum, RS Goldberg, RB Livingston. <u>Cancer</u> 64(12):2409-2415, 1989.	Breast	04/15/86	01/01/88

ABSTRACTS PUBLISHED/PRESENTED

*7436	Adjuvant combination chemotherapy (CMFVP) vs L-phenylalanine mustard (LPAM) for operable breast cancer with positive axillary lymph nodes: 10 year results. S Rivkin, S Green, CK Osborne, B Metch, H Glucksberg, R McDivitt, N Gad-el-Mawla, R Stephens, J Costanzi. <u>ASCO</u> 8:24 (#89), 1989.	Breast	01/09/75	07/18/79
*7827	Adjuvant chemotherapy for poor prognosis estrogen receptor negative stage II-III breast cancer; a comparison of one year vs two years CMFVP. S Green, S Rivkin, B Metch, CK Osborne, A Cruz, S Balcerzak, R Stevens, J Costanzi. <u>ASCO</u> 8:24 (#88), 1989.	Breast	07/16/79	04/01/89

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1988**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8020	VP-16 + adriamycin vs. adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: A Southwest Oncology Group study. CB Vaughn, SJ Green, R O'Bryan, M Reed, PN Grozea, WS Fletcher, JB Green, B Metch, N Oishi. <u>Medical & Pediatric Oncology</u> 16:312-319, 1988.	Breast	09/26/80	12/23/82
ABSTRACTS PUBLISHED/PRESENTED				
8294	Efficacy of adjuvant chemotherapy inoperable node-negative breast cancer. an intergroup study EST 1180. EG Mansour, R Gray, AH Shatila, CK Osborne, DC Tormey, KG Gilchrist, R Cooper, G Falkson. <u>11th Annual San Antonio Breast Cancer Symposium, Breast Cancer Res Treat</u> 12:107, 1988.	Breast	05/15/86	05/15/88
8568	Increase in proliferation fraction in breast cancer in vivo following estradiol vaginal suppositories as demonstrated by serial biopsies and flow cytometry. C Fabian, C Park, W Jewell, B Kimler, F Lin, S Martino, CK Osborne. <u>AACR</u> 29:236, 1988.	Breast	03/04/86	11/15/90
8571	Non-alkylator induction and high-dose cyclophosphamide (CTX) consolidation in poor-risk, disseminated breast cancer. A Southwest Oncology Group (SWOG) study. RB Livingston, BL Trantum, S Schulman. <u>ASCO</u> 7:18 (#69), 1988.	Breast	04/15/86	01/01/88

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1987**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

8274	Short-term chemotherapy of poor-prognosis metastatic breast cancer with three non-cross resistant chemotherapy regimens: A Southwest Oncology Group study. FR Ahmann, R Pugh. <u>Cancer</u> 59(2):239-244, 1987.	Breast	01/31/83	10/03/84
8278	Combination chemotherapy and systemic irradiation consolidation for poor prognosis breast cancer. RB Livingston, S Schulman, BR Griffin, BL Trantum, SE Rivkin, RS Goldberg, CJ Fabian, N Hammond, H Hynes. <u>Cancer</u> 59:1249-1254, 1987.	Breast	06/24/83	09/27/85

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1986**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
Multiple Studies	Adjuvant therapy of breast cancer: Southwest Oncology Group studies. CK Osborne, SE Rivkin, RW McDivitt, S Green, RL Stephens, JJ Costanzi, R O'Bryan. <u>NCI Monographs</u> 1:71-74, 1986.	Breast		
ABSTRACTS PUBLISHED/PRESENTED				
*7436	Adjuvant chemotherapy for operable breast cancer with positive axillary nodes. H Glucksberg, SE Rivkin, S Green, B Metch, CK Osborne, R McDivitt, R Stevens, J Costanzi. <u>ASCO</u> 5:68 (#265), 1986.	Breast	01/09/75	07/18/79
7827	Adjuvant chemotherapy for poor prognosis estrogen receptor negative stage II, III breast cancer one year versus two years CMFVP. S Rivkin, S Green, B Metch, CK Osborne, WA Knight, R McDivitt, A Cruz, D Tesh, J Costanzi, S Balcerzak, R Stevens. <u>ASCO</u> , #C-266, 1986.	Breast	07/16/79	08/01/89
*8203/04	Randomized trial of novantrone (N), bisantrene (B), and adriamycin (A) in advanced breast cancer. JD Cowan, CK Osborne, JJ Costanzi, BA Neilan, JN Bickers, JA Neidhart, M Heller. <u>ASCO</u> 5: 59 (#228), 1986.	Breast	12/23/82	
8278	Sequential hemibody irradiation (HBI) or cyclophosphamide (CTX) + total body irradiation (RBI) + autologous bone marrow infusion (ABM) as consolidation for estrogen receptor, negative, disseminated breast cancer. A Southwest Oncology Group Study. R. Livingston, B Griffin, S Schulman. <u>AACR</u> 27:205 (#812), 1986.	Breast	06/24/83	09/27/85

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1985**

NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8076	Prognostic effects of estrogen receptor in disseminated breast cancer: A Southwest Oncology Group study. J Mortimer, N Flourney, RB Livingston, RL Stephens. <u>Cancer</u> 56:2376-2380, 1985.	Breast	10/21/80	09/10/82
8203	A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer . A Southwest Oncology Group study. JD Cowan, CK Osborne, JA Neidhart, DD Von Hoff, JJ Costanzi, CR Vaughn. <u>IND</u> 3:149-152, 1985.	Breast	12/23/82	
8203/8204 (1100)	The Southwest Oncology Group randomized trial of novantrone [®] , adriamycin [®] , and bisantrene in advanced breast cancer. CK Osborne, JD Cowan, JA Neidhart, H Loveless, DD Von Hoff, JJ Costanzi, CB Vaughn. <u>The Current Status of Novantrone</u> , John Wiley and Sons 55-58, 1985.	Breast		
Multiple Studies	Short-term cryopreservation of human breast carcinoma cells for flow cytometry. KR Stone, RB Craig, JO Palmer, SE Rivkin, RW McDivitt. <u>Cytometry</u> 6:357-361, 1985.	Breast		
ABSTRACTS PUBLISHED/PRESENTED				
8274	Short term treatment of poor prognosis metastatic breast cancer with three alternating chemotherapy regimens: A Southwest Oncology Group pilot study. FR Ahmann, R Pugh. <u>ASCO</u> , #C-264, 1985.	Breast	01/31/83	10/03/84

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1984**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7436	Adjuvant therapy of breast cancer: A Southwest Oncology Group experience. SE Rivkin, H Glucksberg, M Foulkes. <u>Recent Results Cancer Res</u> 96:166-74, 1984.	Breast		
7632	Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study. B Hoogstraten, N Gad-el-Mawla, TR Maloney, WS Fletcher, CB Vaughn, BL Trantum, JW Athens, JJ Costanzi, M Foulkes. <u>Cancer</u> 54:2248-2256, 1984.	Breast		
7921	Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in advanced breast cancer. A Phase II trial of the Southwest Oncology Group. WA Knight III, RM O'Bryan, B Samal, JJ Costanzi. <u>Invest New Drugs</u> 2:71-73, 1984.	Breast		
ABSTRACTS PUBLISHED/PRESENTED				
7436	Adjuvant chemotherapy for operable breast cancer with positive axillary nodes. S Rivkin, H Glucksberg, M Foulkes. <u>ASCO</u> , #C-488, 1984.	Breast		
*7725	Levamisole (L) probably shortens response and survival in CMFP-maintained advanced breast cancer patients. A Southwest Oncology Group study. BA Samal, MA Foulkes, B McDonald. <u>ASCO</u> , #C-495, 1984.	Breast		
*7827	Adjuvant chemotherapy and hormonal therapy for operable breast cancer with positive axillary nodes. SE Rivkin, WA Knight III, A Cruz, M Foulkes, R McDivitt. <u>AACR</u> , #717, 1984.	Breast		
*8020	Adriamycin + VP-16 vs. Adriamycin alone in advanced adenocarcinoma of the breast, Phase II: A Southwest Oncology Group study. CB Vaughn, R O'Bryan, M Reed, P Grozea, W Fletcher, B Green, MA Foulkes. <u>AACR</u> , #729, 1984.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1983**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7436/7827	Adjuvant therapy of breast cancer: The Southwest Oncology Group experience. WA Knight III, SE Rivkin, H Glucksberg, MA Foulkes, JJ Costanzi, RL Stephens, JW Athens, RM O'Bryan. <u>Breast Cancer Res & Treat</u> 3(Suppl 1):27-33, 1983.	Breast		
7726	Phase II evaluation of rubidazone (NSC-164011) in advanced carcinoma of the breast. A Southwest Oncology Group study. FE Smith, N Gad-el-Mawla, B Trantum, LH Baker, FJ Panettiere, JW Athens, M Foulkes. <u>Investigational New Drugs</u> 1: 315-319, 1983.	Breast		
7963	Phase II evaluation of Amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: A University of Arizona and Southwest Oncology Group study. FR Ahmann, F Meyskens Jr, SE Jones, RM Bukowski, JH Saiers, DH Ryan, J Costanzi, CB Vaughn, CA Coltman Jr. <u>Cancer Treat Rep</u> 67:697-700, 1983.	Melanoma, Myeloma, Lymphoma, Lung, Breast		
8008	Mitoxantrone in advanced breast cancer: A Phase II trial of the Southwest Oncology Group. WA Knight, DD Von Hoff, JA Neidhart, BL Trantum, C Fabian, SE Jones. <u>Investigational New Drugs</u> 1:181-184, 1983.	Breast		

ABSTRACTS PUBLISHED/PRESENTED

7436	Adjuvant chemotherapy for operable breast cancer with positive axillary nodes. S Rivkin, H Glucksberg, M Foulkes. <u>ASCO</u> , #C-390, 1983.	Breast		
7827	Adjuvant chemotherapy and hormonal therapy for operable breast cancer with positive axillary nodes. A Cruz, S Rivkin, WS Knight, R McDivitt, D Tesh, M Foulkes. <u>ASCO</u> , #C-383, 1983.	Breast		
7827	Adjuvant chemohormonal therapy for operable breast cancer: A SWOG study. S Rivkin, WA Knight, M Foulkes. <u>Breast Cancer Res Treat</u> 3:306, 1983.	Breast		
*8076	Aggressive chemotherapy for estrogen receptor (ER) negative metastatic breast cancer (MBC). For the Southwest Oncology Group. R Livingston, C Fabian, S Rivkin, C Vaughn. <u>AACR</u> , #563, 1983.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1982**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7405B	Adriamycin combinations in advanced breast cancer. BL Trantum, T Thigpen, C Vaughn, H Wilson, T Maloney, J Costanzi, J Bickers, N Gad-el-Mawla, R Palmer, B Hoogstraten, L Heilbrun, S Rasmussen. <u>Cancer</u> 49: 835-839, 1982.	Breast		
7436	Combination chemotherapy (CMFVP) versus L-Phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: A Southwest Oncology Group study. H Glucksberg, SE Rivkin, S Rasmussen, B Trantum, N Gad-el-Mawla, J Costanzi, B Hoogstraten, J Athens, T Maloney, J McCracken, C Vaughn. <u>Cancer</u> 50:423-434, 1982.	Breast		
7632	Tamoxifen and oophorectomy in the treatment of recurrent breast cancer. A Southwest Oncology Group study. B Hoogstraten, WS Fletcher, N Gad-el-Mawla, T Maloney, SJ Altman, C Vaughn, MA Foulkes. <u>Cancer Res</u> 42: 4788-4791, 1982.	Breast		
7917	Phase II evaluation of Gallium Nitrate in breast cancer: A Southwest Oncology Group study. CJ Fabian, LH Baker, CB Vaughn, HE Hynes. <u>Cancer Treat Rep</u> 66:1591, 1982.	Breast		
ABSTRACTS PUBLISHED/PRESENTED				
*7436	Adjuvant chemotherapy for operable breast cancer with positive axillary nodes. S Rivkin, H Glucksberg, M Foulkes. <u>ASCO</u> , #C-285, 1982.	Breast		
7514	Phase II evaluation of VP-16-213 in patients with advanced breast cancer. CB Vaughn. <u>Oncology Digest</u> , 5-6, June 1982.	Breast		
*7632	The role of Tamoxifen in predicting response to ovarian ablation in patients with recurrent breast cancer. B Hoogstraten. <u>ASCO</u> , #C-275, 1982.	Breast		
7827	Adjuvant chemotherapy and hormonal therapy for operable breast cancer with positive axillary nodes. A Cruz, S Rivkin, WA Knight, R McDivitt, D Tesh, M Foulkes, JB Aust. <u>ASCO</u> , #C-317, 1982.	Breast		
8008	Phase II trial of dihydroxyanthracenedione (DHAD, Mitoxantrone) in breast cancer: A Southwest Oncology Group study. WA Knight III, DD Von Hoff, B Trantum, R O'Bryan. <u>ASCO</u> , #C-335, 1982.	Breast		
8076	Adriamycin-containing chemotherapy as a determinant of response in estrogen-receptor negative disseminated breast cancer. RB Livingston, RP Pugh. <u>AACR</u> , #595, 1982.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1981**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7436	Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: A comparison of CMFVP versus L-Pam (Southwest Oncology Group Study). In: <u>Adjuvant Therapy of Cancer III</u> . SE Jones and SE Salmon, eds. Grune and Stratton, 1981.	Breast		
7514	Phase II evaluation of 4-demethyl-E-pipodophyl-lotoxin-B-dethylidone glucoside (VP-16-213) (NSC-14150) in patients with advanced breast cancer: A Southwest Oncology Group study. CB Vaughn, F Panettiere, T Thigpen, R Bottomley, B Hoogstraten, B Samal. <u>Cancer Treat Rep</u> 65:443-445, 1981.	Breast		

ABSTRACTS PUBLISHED/PRESENTED

7436	Adjuvant chemotherapy for operable breast cancer with positive axillary nodes. H Glucksberg, S Rivkin, S Rasmussen. <u>ASCO</u> , #C-367, 1981.	Breast		
7921	Methyl-Glyoxal Bis-Guanyl Hydrazone (Methyl-GAG, MGBG) in advanced breast cancer - A Phase II trial. G Sledge, WA Knight III, CJ Fabian. <u>ASCO</u> , #C-407, 1981.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1980**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7809	Minimal single agent activity of Maytansine in refractory breast cancer. JA Neidhart, LR Laufman, C Vaughn, JD McCracken. <u>Cancer Treat Rep</u> 64: 675-677, 1980.	Breast		
------	--	--------	--	--

ABSTRACTS PUBLISHED/PRESENTED

7963	A broad Phase II trial of AMSA with <u>in vitro</u> stem cell culture drug sensitivity correlation. F Ahmann, F Meyskens, S Jones, B Durie, D Alberts, S Salmon. <u>ASCO</u> , #C-199, 1980.	Breast, Lung, Lymphoma, Melanoma, Myeloma		
------	--	---	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1979**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7436	Adjuvant chemotherapy for stage II breast cancer: A comparison of CMFVP versus L-PAM (Southwest Oncology Group study). H Glucksberg, SE Rivkin, S Rasmussen. In: <u>Adjuvant Therapy of Cancer II</u> , pp. 261-268, 1979.	Breast		
7636	Phase II evaluation of hexamethylmelamine in advanced breast cancer: A Southwest Oncology Group study. CJ Fabian, S Rasmussen, R Stephens, A Haut, F Smith, S Balcerzak, B Trantum. <u>Cancer Treat Rep</u> 63(8):1359-1361, 1979.	Breast		

ABSTRACTS PUBLISHED/PRESENTED

7436	Adjuvant chemotherapy in stage II breast cancer: S Rivkin, H Glucksberg, S Rasmussen. <u>ASCO</u> #C-255, 1979.	Breast		
7436	Adjuvant chemotherapy in stage II breast cancer: H Glucksberg, S Rivkin. <u>International Conference on the Adjuvant Therapy of Cancer</u> #53, 1979.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1978**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
450	Prognostic factors in the initial response to therapy by patients with advanced breast cancer. George et al. 1978.	Breast		
7405	Adriamycin in combination for the treatment of breast cancer. B Trantum, B Hoogstraten, A Kennedy, CB Vaughn, B Samal, T Thigpen, SE Rivkin, F Smith, RL Palmer, J Costanzi, WG Tucker, H Wilson, TR Maloney. <u>Cancer</u> 41(6):2078-2083, 1978.	Breast		
7408	Chromomycin A for advanced breast cancer: A Southwest Oncology Group study. B Samal, S Jones, RW Brownlee, F Morrison, B Hoogstraten, E Caoili, L Baker. <u>Cancer Treat Rep</u> 62(1):19-22, 1978.	Breast		
7437	Cyclocytidine in breast cancer. RM O'Bryan, LH Baker, J Whitecar, SE Salmon, C Vaughn, B Hoogstraten. <u>Cancer Treat Rep</u> 62(3):455-456, 1978.	Breast		
7505	Adriamycin and CCNU in advanced breast cancer. R Watt, J Saiki, B Trantum, B Hoogstraten. <u>Cancer Clinical Trials</u> , pp. 9-11, 1978.	Breast		
7508	Studies with 2,5-piperazinedione 3,6-Bis (5 chloro-2-piperidyl) - dihydrochloride (NSC-135758), in breast carcinoma. RL Palmer, CB Vaughn, BL Trantum. <u>Current Chemotherapy</u> , pp. 1212-1213, 1978.	Breast		
7520	1,2:5,6 dianhydrogalactitol in advanced breast cancer. B Hoogstraten, RM O'Bryan, S Jones. <u>Cancer Treat Rep</u> 62(5):841-842, 1978.	Breast		
ABSTRACTS PUBLISHED/PRESENTED				
7405	Update: Treatment of advanced breast cancer. A 3-arm prospective study. B Trantum, L Heilburn, B Hoogstraten. <u>ASCO</u> 19:340 (#C-133), 1978.	Breast		
7408	Chromomycin A3 for advanced breast cancer: A Southwest Oncology Group study. B Samal, S Jones, BW Brownlee, FS Morrison, B Hoogstraten, E Caoili, L Baker. <u>Cancer Therapy Abstracts</u> 78:2329, 1978.	Breast		
7636	Hexamethylmelamine with or without pyridoxine in refractory breast cancer. C Leite. <u>ASCO</u> (#C-341), 1978.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1977**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

450	Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. B Hoogstraten, SL George, B Samal, SE Rivkin, JJ Costanzi, JD Bonnet, T Thigpen and H Braine. <u>Cancer Treat Rep</u> 61:1485-1487, 1977.	Breast		
7508	Phase II evaluation of piperazinedione in metastatic breast carcinoma. RL Palmer, BA Samal, CB Vaughn and BL Trantum. <u>Cancer Treat Rep</u> 61:1711-1712, 1977.	Breast		

ABSTRACTS PUBLISHED/PRESENTED

7405	Treatment of advanced breast cancer. A 3-arm prospective study. BL Trantum. <u>ASCO</u> , #C-31, 1977.	Breast		
7405	Breast cancer: CNS metastasis while receiving systemic chemotherapy. BL Trantum. <u>AACR</u> , #298, 1977.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1976**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
450	Combination chemotherapy and adriamycin in patients with advanced breast cancer. B Hoogstraten, SL George, B Samal, SE Rivkin, JJ Costanzi, JD Bonnet, T Thigpen, H Braine. <u>Cancer</u> 38(7):13-20, 1976.	Breast		
ABSTRACTS PUBLISHED/PRESENTED				
*7405	Adriamycin in combination for treatment of breast cancer. B Trantum, B Hoogstraten and A Kennedy. <u>ASCO</u> , #C-22, 1976.	Breast		
*7437	Cyclocytidine in breast carcinoma. RM O'Bryan, SE Salmon, LH Baker and C Vaughn. <u>ASCO</u> , #C-250, 1976.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1975**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
450	Adriamycin in the treatment of advanced breast cancer. B Hoogstraten. <u>Cancer Chemotherapy Reports</u> 6: 329-334, 1975.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1974**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
449	Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. JA Gottlieb, SE Rivkin, SC Spigel, B Hoogstraten, RM O'Bryan, FC Delaney and A Singhakowinta. <u>Cancer</u> 33:519-526, 1974.	Breast		
ABSTRACTS PUBLISHED/PRESENTED				
450	Adriamycin and combination chemotherapy in advanced breast cancer. B Hoogstraten and SL George. <u>AACR</u> , 1974.	Breast		
450	Adriamycin and combination chemotherapy in advanced breast cancer. B Hoogstraten. <u>XI International Cancer Congress</u> , Florence, Italy, 1974.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1973**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
1437	Response of advanced breast cancer to two dosage regimens of 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962). JD Bonnet, RW Brownlee, VK Vaitkevicius, RW Talley. <u>Cancer Chemotherapy Reports</u> 57(2): 231-234, 1973.	Breast		
917	Combination chemotherapy in the treatment of disseminated breast carcinoma. SC Spigel, CA Coltman, Jr, JJ Costanzi. <u>Arch Intern Med</u> 132:575, 1973.	Breast		
ABSTRACTS PUBLISHED/PRESENTED				
450	Adriamycin and combination chemotherapy in breast cancer. B Hoogstraten. <u>AACR</u> , 1973.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1972**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

?	Re-evaluation of rebound regression in disseminated carcinoma of the breast. LH Baker and VK Vaitkevicius. <u>Cancer</u> 29:1268-71, 1972.	Breast		
---	--	--------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1966**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Melphalan (NSC-8806) in advanced breast cancer. ME Sears, A Haut, N Eckles. <u>Cancer Chemotherapy Reports</u> 50:271-279, 1966.	Breast		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1964**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

?	Phase II studies of hydroxyurea (NSC-32065) in adults: Cancer of the breast. ME Sears. <u>Cancer Chemotherapy Reports</u> 40:43, 1964.	Breast		
---	---	--------	--	--